

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/74, 15/68, 1/21, A23C 3/08 // (C12N 1/21, C12R 1:225)		A1	(11) International Publication Number: WO 95/10621 (43) International Publication Date: 20 April 1995 (20.04.95)
(21) International Application Number: PCT/DK94/00376 (22) International Filing Date: 7 October 1994 (07.10.94) (30) Priority Data: 08/133,390 8 October 1993 (08.10.93) US 08/242,098 13 May 1994 (13.05.94) US (60) Parent Application or Grant (63) Related by Continuation US 08/242,098 (CIP) Filed on 13 May 1994 (13.05.94) (71) Applicant (for all designated States except US): CHR. HANSEN'S LABORATORIUM DANMARK [DK/DK]; Bøge Allé 10-12, P.O. Box 407, DK-2970 Hørsholm (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): DICKELY, Françoise [FR/FR]; 2 bis, rue Poincaré, F-67210 Obernai (FR). JO- HANSEN, Eric [CA/DK]; Gøgevang 8, DK-2970 Hør- sholm (DK). NILSSON, Dan [DK/DK]; 3rd floor, Hjelms- gade 7, DK-2100 Copenhagen (DK). HANSEN, Egon, Bech [DK/DK]; Dalvangen 22, DK-2700 Brønshøj (DK).			(74) Agent: PLOUGMANN & VINGTOFT A/S; Sankt Annæ Plads 11, P.O. Box 3007, DK-1021 Copenhagen K (DK). (81) Designated States: AM, AT, AT (Utility model), AU, BB, BG, BR, BY, CA, CN, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, FI, FI (Utility model), GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, SK (Utility model), TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). Published <i>With international search report.</i>
(54) Title: LACTIC ACID BACTERIAL SUPPRESSOR MUTANTS AND THEIR USE AS SELECTIVE MARKERS AND AS MEANS OF CONTAINMENT IN LACTIC ACID BACTERIA			
(57) Abstract Mutants of lactic acid bacteria or plasmids capable of replicating in lactic acid bacteria, comprising nonsense mutation suppressor- encoding genes, the use of such suppressor genes for confining a replicon to a specific lactic acid bacterium or to a lactic acid bacterium growing in a particular environment and for controlling the number of lactic acid bacterial cells in a particular environment.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

LACTIC ACID BACTERIAL SUPPRESSOR MUTANTS AND THEIR USE AS
SELECTIVE MARKERS AND AS MEANS OF CONTAINMENT IN LACTIC ACID
BACTERIA

FIELD OF INVENTION

- 5 The present invention provides useful mutants of lactic acid
bacteria or plasmids capable of replicating in lactic acid
bacteria, comprising nonsense mutation suppressor-encoding
genes, the use of such suppressor genes for confining a
replicon to a specific lactic acid bacterium or to a lactic
10 acid bacterium growing in a particular environment and for
controlling the number of lactic acid bacterial cells in a
particular environment.

TECHNICAL BACKGROUND AND PRIOR ART

- In the in vivo synthesis of proteins occurring in the riboso-
15 mes, mRNA is translated into polypeptide chains. However, the
mRNA codons do not directly recognize the amino acids that
they specify in the way that an enzyme recognizes a substra-
te. Translation uses "adaptor" molecules that recognize both
an amino acid and a triplet group of nucleotide bases (a
20 codon). These adaptors consist of a set of small RNA molecu-
les known as transfer RNAs (or tRNAs), each of which is only
70 to 90 nucleotides in length. Such tRNA molecules contain
unpaired nucleotide residues comprising a CCA triplet at one
end of the molecule and, in a central loop, a triplet of
25 varying sequence forming the so-called anticodon that can
base-pair to a complementary triplet in the mRNA molecule,
while the CCA triplet at the free 3' end of the molecule is
attached covalently to a specific amino acid.

- The three nucleotide triplets UAG (amber codon), UGA (opal
30 codon) and UAA (ochre codon) do not code for an amino acid.
These signals termed stop codons or "nonsense" codons, are
involved in polypeptide chain termination. During transla-
tion, two protein factors (R1 and R2) recognize these trip-

lets and effect release of the polypeptide chain from the ribosome-mRNA-tRNA complex.

Occasionally a mutation occurs in a cell resulting in a nonsense codon appearing in the middle of a gene, causing premature chain termination and the production of a protein fragment. Such fragments rarely have enzymatic activity.

The effect of such a nonsense mutation can be reversed or suppressed by a second mutation in a gene coding for a tRNA which results in the synthesis of an altered tRNA molecule. Such an altered tRNA recognizes a nonsense codon and inserts an amino acid at that point in the polypeptide chain. The mutated tRNA-encoding gene is termed a suppressor gene and the altered nonsense mutation-suppressing tRNA which it encodes is generally referred to as a nonsense or termination suppressor. Such termination suppressors may be derived by single, double or triple base substitutions in the anticodon region of the tRNA.

Termination suppressors were first detected in *E. coli* about 25 years ago and have since been extensively studied in this species. It is considered that all termination suppressors in *E. coli* have been identified. Recently, new suppressor tRNA genes have been synthesized in vitro and subsequently introduced into *E. coli*. Termination suppressors have also been identified in the *E. coli* bacteriophage T4 and in *Salmonella typhimurium* (Eggertson et al., 1988, Microbiological Reviews, 52, 354-374). Furthermore, termination suppressors have been identified in eucaryotic fungi including *Neurospora* spp., *Saccharomyces cerevisiae* and *Schizosaccharomyces pombe*.

Hitherto, nonsense or termination suppressors have not been identified in bacterial species belonging to the industrially important group of lactic acid bacteria which i.a. are commonly utilized as starter cultures in the production of a variety of food products including dairy products, meat products, vegetable products, bakery products and wine,

during which production these starter cultures produce lactic acid and other organic acids and in many instances also desirable flavour-enhancing metabolites.

Furthermore, attempts by the present inventors to construct
5 amber-suppressing strains of lactic acid bacteria by introducing cloned known suppressor genes from *E. coli* proved unsuccessful. Thus, it was attempted to introduce the *E. coli supB* gene (Thorbjarnadottir et al., 1985), the *E. coli supE* gene (Nakajima et al., 1981) and the *E. coli supF* gene (Ryan et
10 al., 1980). These three suppressor genes were moved to pFDi3 described in the below Example 3 and analyzed for suppressor activity in *Lactococcus lactis* by testing for the expression of erythromycin resistance. None of the three *E. coli* suppressor genes expressed suppressor activity in *Lactococcus*
15 *lactis*.

In many instances it is advantageous to use lactic acid bacterial starter cultures which are composed of two or more different species, since the metabolic activity of one species may enhance the growth of an other species or because
20 different lactic acid bacterial species may have particularly advantageous effects on flavour development of the food product at specific stages of the food production.

Accordingly, an industrial need exists to provide mixed lactic acid bacterial starter cultures in which a particular
25 characteristic is confined (or contained) to a particular strain. Commonly, genes coding for desired characteristics of a lactic acid bacterium are located on extrachromosomal replicons such as plasmids. It may therefore be advantageous to have such replicons contained in their original host
30 species. As used herein, the term "contained" indicates confinement of a replicon to a specific host cell or to the stable maintenance of a replicon in a lactic acid bacterial host cell when this host cell is present in a specific environment. This stable maintenance in a particular host cell

of a replicon may also be referred to as stabilization of that replicon.

The term "containment" may also as used herein as encompassing the phenomenon that the growth and/or viability of a specific lactic acid bacterial strain in a particular environment is controlled.

The known methods of stably maintaining (stabilizing) replicons to a host cell involve the insertion of relatively large DNA sequences such as a partitioning function. However, as it is well-known, the insertion of large DNA sequences involves the risk of deletion of other sequences from the replicon. It has now been found that nonsense suppressor-encoding lactic acid bacterial strains may be developed which provide the means of a novel and advantageous method of confining replicons to lactic acid bacterial strains. In contradistinction to the known methods of stabilizing (confining) replicons to host cells, the method as defined herein makes use of genes coding for suppressor tRNA which are small and may be inserted without causing deletions of desired genes.

In the production of food products where live microorganisms are used, it may be critical for the obtainment of the desired quality of the products that the microbial processes can be controlled effectively. This is particularly important when mixed starter cultures as defined above and which comprise a multiplicity of strains, are used. Such a control has hitherto been difficult to achieve since specific regulating mechanisms at the level of cell numbers and activity and at the level of gene expression in particular strains had to be selected individually for each of the strains used in the mixed culture. However, the present invention has made it possible that the same suppressor gene under the control of the same regulatory mechanism may be inserted in all of the strains of the mixed starter culture whereby the activity of the species of such a culture may be regulated concomitantly or, if different regulatory sequences are inserted in in-

dividual species members of the starter culture, the activity of the individual members may be regulated independently.

SUMMARY OF THE INVENTION

Accordingly, the present invention relates in a first aspect to a method of isolating a nonsense suppressor-encoding lactic acid bacterium, comprising the steps of (i) mutagenizing a replicon capable of replicating in a lactic acid bacterium, said replicon comprising a gene encoding a selectable marker which is expressible in the lactic acid bacterium, (ii) selecting from the mutagenized replicon of (i) a replicon containing a nonsense mutation in the gene encoding the selectable marker, (iii) mutagenizing a lactic acid bacterium which does not encode a nonsense suppressor, (iv) introducing the replicon of step (ii) into said mutagenized lactic acid bacterium, and (v) selecting from the mutagenized lactic acid bacterium of (iv) a nonsense suppressor-encoding transformed lactic acid bacterium in which the selectable marker is expressed.

In another aspect there is provided a method of isolating a nonsense suppressor-encoding lactic acid bacterium, comprising the steps of (i) mutagenizing a replicon without nonsense mutations but containing a selectable marker, which plasmid is inherently capable of replicating in a lactic acid bacterium, (ii) selecting from step (i) a replicon containing a nonsense mutation rendering the replicon incapable of replicating, (iii) mutagenizing a lactic acid bacterium which does not encode a nonsense suppressor, (iv) introducing into said mutagenized lactic acid bacterium the replicon of step (ii), and (v) selecting a transformed lactic acid bacterium in which the introduced replicon is capable of replicating.

In further aspects, the present invention also relates to an isolated pure culture of a lactic acid bacterium comprising a gene coding for a nonsense suppressor, to a composition

comprising such an isolated pure culture of a lactic acid bacterium as defined herein, and a carrier, and to the use of the composition as a starter culture in the preparation of a food product selected from a dairy product, a vegetable
5 product, a meat product and a bakery product.

The invention also pertains to a plasmid comprising lactobacterial DNA and capable of replicating in a lactic acid bacterium, the plasmid comprising a gene coding for a nonsense suppressor.

10 In one interesting aspect, the invention relates to a method of confining an extrachromosomal replicon capable of replicating in lactic acid bacteria to a first kind of lactic acid bacterial cells, where said replicon could be naturally transferred to a second kind of lactic acid bacterial cells,
15 which method comprises providing the first kind of lactic acid bacterial cells as cells containing a nonsense suppressor-encoding gene, the cells being transformed with the replicon in the form of a nonsense mutant hereof having lost its capability of replicating in lactic acid bacterial cells,
20 the gene product of the nonsense suppressor-encoding gene being capable of restoring the capability of the replicon to replicate in lactic acid bacterial cells whereby, if a cell of the second kind which does not contain a nonsense suppressor gene encoding a gene product capable of restoring the
25 capability of the nonsense mutant of the replicon to replicate in lactic acid bacteria, receives said extrachromosomal replicon, the replicon will not replicate in the second kind of lactic acid bacterial cell.

In a further interesting aspect, the present invention relates to a method of stably maintaining an extrachromosomal replicon in lactic acid bacterial host cells growing in a particular environment, comprising providing said host cells as nonsense mutant cells having lost the capability of growing in said environment, and transformed with an extra-
35 chromosomal replicon containing a nonsense suppressor gene

encoding a gene product restoring the capability of the nonsense mutant cells to grow in said environment whereby, if the replicon is lost from the lactic acid bacterial cells, the cells will not grow.

- 5 In a still further aspect the present invention provides a method of controlling the number of lactic acid bacterial cells in a particular environment allowing growth of lactic acid bacteria, comprising providing the bacteria with a nonsense mutation in a gene the expression of which has an
10 effect on the viability or the growth of the bacteria, and inserting in the bacteria a nonsense suppressor-encoding gene under the control of a regulatable promoter, the gene product of which, when expressed at one level, prevents the expression of the nonsense mutation and which, when not expressed,
15 or expressed at a different level causes the cells to cease growth or to die.

DETAILED DISCLOSURE OF THE INVENTION

- As mentioned above, the method of isolating a nonsense suppressor-encoding lactic acid bacterium comprises as an initial
20 step the provision of a replicon capable of replicating in the lactic acid bacterium, which replicon contains a nonsense mutation in a gene coding for a selectable marker (a marker gene) and preferably also a non-mutated gene coding for a further selectable gene product. The selectable marker gene
25 may be selected from any gene coding for a readily detectable phenotype such as a gene the expression of which confers resistance to an antibiotic to which the lactic acid bacterium is sensitive, including as examples resistance to erythromycin, chloramphenicol or tetracycline. Other useful
30 mutant markers include auxotrophic phenotypes such as Pur⁻ chromosomal mutants or replicons such as plasmid or bacteriophage mutants having lost their inherent capability of replicating in the lactic acid bacterium.

In accordance with the present invention, any suitable conventional mutagen including ultraviolet and ionizing radiation and chemical mutagens including mutagens which affect non-replicating DNA such as HNO_2 , NH_2OH ; alkylating agents including as examples ethyl methane sulphonate (EMS) and N-methyl-N'-nitro-N-nitrosoguanidine (NTG); and base analogs or frameshift mutagens, may be used for mutating the marker gene. Furthermore, mutagenesis may be site-directed mutagenesis, using recombinant DNA techniques including the use of primers in the polymerase chain reaction, of transposable elements or bacterial mutator strains, e.g. the mutator strain LE30.

Although the nonsense mutation as defined above may most conveniently be provided by subjecting the replicon to a mutagenization treatment as also defined above, it is not excluded that a replicon containing a nonsense mutation in the gene coding for a selectable marker may be an isolated spontaneous mutant.

In the following, a nonsense mutation is designated by the conventional designation of the gene in which the mutation has occurred, followed by an indication of the type of nonsense mutation. Thus, a nonsense mutation recognizable by either an amber or ochre suppressor, in genes coding for erythromycin and chloramphenicol resistance, respectively is designated *erm-am* and *cat-am*, respectively.

In certain embodiments of the invention, the mutated replicon may contain two or more nonsense mutations, e.g. in genes coding for antibiotic resistance such as *erm-am* and *cat-am*. Such replicons containing multiple nonsense mutations may conveniently be constructed by recombining in one replicon DNA sequences containing the mutations. Thus, as one example which is described in details in the following, a starting plasmid may be isolated which contains a nonsense mutation in the *erm* gene. In a subsequent step, a DNA sequence comprising this gene may be inserted in an other plasmid carrying a

nonsense mutation in the *cat* gene. A typical example of such a replicon containing two nonsense mutations is the plasmid pFDi10 as described below.

When an isolated nonsense replicon mutant is obtained, it is
5 used as a means of isolating a lactic acid bacterium in which a nonsense suppressor mutation has been generated by subjecting a population of a parent lactic acid bacterium which does not encode a suppressor mutant, to a treatment with a mutagen as defined above. The mutant replicon is introduced by means
10 of conventional transformation techniques into a population of the thus mutagenized lactic acid bacterial cells and a nonsense suppressor mutant cell is selected from these transformed cells by growing the cells under conditions allowing the replicon marker gene to be expressed and isolating host
15 cells in which the nonsense mutation in the replicon is expressed. When e.g. the mutation in the replicon is in a gene conferring resistance to one or more antibiotics, a nonsense suppressor-encoding mutant of the transformed lactic acid bacterial cells may conveniently be selected from a
20 medium containing this/these antibiotic(s).

That a transformed cell capable of growing in such a selective medium is a true suppressor-encoding cell may subsequently be verified by (i) transforming the same non-sense mutation-containing replicon to known suppressor host cells
25 in which the replicon can replicate and to corresponding host cells without the suppressor gene and (ii) reintroducing the replicon into the assumed suppressor-encoding cell to confirm the suppressor phenotype.

The thus obtained nonsense-suppressing transformants may
30 subsequently be cured of the replicon e.g. by growing the transformants in a non-selective medium or by treating them with a conventional plasmid curing agent.

The suppressor gene may be located on the chromosome or on an extrachromosomal replicon.

Most mutations in a tRNA-encoding gene leading to the formation of a nonsense suppressor are located in the anticodon triplet and alter it to CUA, UUA or UCA. Such suppressors may be referred to as amber, ochre and opal suppressors, respectively. Following the rules of nomenclature of Demerec et al. (Genetics, 1966, 54, 61-76) which was suggested for termination (nonsense) suppressors in *E. coli* the symbol "sup" and assigned capital letters as gene designations, e.g. *supB*, *supC* or *supZ*, are used herein also to designate suppressor genes in lactic acid bacteria. In this system, the term *sup*⁺ (e.g. *supB*⁺) represents the wild-type allele and *sup*⁻ (e.g. *supB*⁻) represents the mutant allele.

Amber suppressors generally recognize only amber codons whereas all ochre suppressors will recognize amber as well as ochre nonsense codons. The spectrum of suppression of a nonsense mutation depends not only on the anticodon (amber or ochre), but also on the amino acid inserted at the nonsense codon. When the suppressor tRNA is causing the insertion of an amino acid which is different from the wildtype protein, the resulting protein may be non-functional. Some nonsense mutations may therefore only be suppressed by one type of suppressors whereas others may be suppressed by several or all suppressors.

Suppressors may show a poor efficiency of suppression which means that the termination of translation at the nonsense codon is not completely suppressed. Thus, a suppressor with an efficiency of 10% will allow only 10% of the protein encoded by a gene with a nonsense mutation to be synthesized in full length whereas 90% of the protein molecules will terminate at the nonsense codon. Most ochre suppressors are only 5% to 10% efficient whilst amber suppressors typically have efficiencies in the range of 25% to 65%.

As it has been mentioned above, the present invention relates in one aspect to a method of isolating a nonsense-suppressor-

encoding lactic acid bacterium in which the replicon being mutagenized to obtain the nonsense mutation is one, which prior to the mutagenesis is capable of replicating in the lactic acid bacterium and which has acquired a nonsense
5 mutation in one or more genes, whereby the isolated mutated replicon is no longer capable of replication in the lactic acid bacterium not containing a suppressor gene, the product of which may suppress the replication nonsense mutation.

Such nonsense mutated replicons having lost their capability
10 of replication may be derived from plasmids or bacteriophages normally replicating in lactic acid bacteria. As one example which is also described in details in the below example 4A, the citrate plasmid of *Lactococcus lactis* subsp. *lactis* biovar *diacetylactis* strain DB1138 may be mutagenized e.g. by
15 means of the polymerase chain reaction to obtain an amber nonsense mutation in the *repB* gene. The replicon from which a non-replicating nonsense mutant may be derived may also be a bacteriophage including as an example the prolate *Lactococcus* phage ϕ MPC100 from which mutants with nonsense mutations in
20 genes essential for phage development may be derived. Such mutants have lost the capability of the parent phage to form plaques on sensitive lactic acid bacteria.

Nonsense mutants of bacteriophages may e.g. suitably be generated by mutagenization with hydroxylamine (NH_2OH).

25 As also mentioned above, there is provided herein an isolated pure culture of a lactic acid bacterium comprising a gene coding for a nonsense suppressor such as a gene coding for amber, ochre or opal suppressor tRNA. Such a gene coding for a termination (nonsense) suppressor may be located on the
30 chromosome of the bacterium or it may in other embodiments be located extrachromosomally e.g. on a plasmid or it may be incorporated in the cell as a prophage.

When the lactic acid bacterium of the above culture is one used as a starter culture in food production, it may be

preferred that the bacterium only contains DNA of lactic acid bacterial origin including DNA isolated from plasmids or other replicons having the lactic acid bacterium as their natural host organism. Accordingly, the nonsense suppressor-
5 containing lactic acid bacterium may in preferred embodiments contain a suppressor gene which is a native gene or which is derived from a heterologous lactic acid bacterium. In the art, recombinant lactic acid bacteria which only contain DNA of lactic acid bacterial origin are also referred to as "food
10 grade" organisms since it is generally considered that the use of such organisms may be allowable by relevant governmental authorities for use in food manufacturing.

As it will be understood from the above, the suppressor gene carried by the pure culture may be an inserted gene either
15 derived from a heterologous lactic acid bacterial strain or from a heterologous lactic acid bacterial plasmid or it may be a suppressor gene derived from the mutagenization of a native, homologous gene which may either be chromosomally or extrachromosomally located. When the gene is an inserted
20 gene, it may be inserted in the chromosome or it may be introduced on a plasmid or a bacteriophage.

In useful embodiments of the invention, the lactic acid bacterial cells of the pure culture may, in addition to the suppressor gene, further comprise a nonsense mutation which
25 is suppressible by the nonsense suppressor. When present in the same cells, the suppressor gene and the gene with the nonsense mutation may preferably be located on different replicons, e.g. so that the suppressor gene is located on the chromosome whereas the nonsense mutation occur in a gene
30 carried by an extrachromosomal replicon. In other useful embodiments, the location of the two genes is the reverse.

In certain preferred embodiments, the suppressor encoded by the lactic acid bacterium constituting the isolated pure culture is an amber suppressor. The suppressor may e.g. be
35 one suppressing a nonsense mutation which, in the absence of

a nonsense suppressor capable of suppressing the mutation, confers auxotrophy such as a nonsense mutation in a gene involved in the synthesis of purine nucleotides from their precursors. Thus the culture may comprise a lactic acid
5 bacterium which is a nonsense *pur* mutant.

Accordingly, in one particularly useful embodiment the lactic acid bacterium in a culture is a strain which contains a nonsense mutation which is suppressed by a suppressor gene located on a food grade plasmid as described above. As an
10 example such a plasmid may be constructed so as to contain a replication region of a lactic acid bacterium or a plasmid naturally occurring in such a bacterium, e.g. the replication region of a plasmid naturally harboured by a *Lactococcus* sp. including the replication region of the citrate plasmid in
15 *Lactococcus lactis* subsp. *lactis* biovar *diacetylactis* and a suppressor gene from a lactic acid bacterium as defined herein such as e.g. a suppressor tRNA gene of *Lactococcus lactis* strain FD100 as described hereinbelow. In such a plasmid the suppressor gene will function as a selectable
20 marker if the nonsense mutation is one which in the absence of a corresponding suppressor gene will render the bacterium incapable of growing in a particular environment, such as milk or any other food product or agricultural product where lactic acid bacteria are used.

25 A plasmid construct as described above will be useful as a cloning vector if further provided with one or more suitable unique restriction sites comprising DNA isolated from a lactic bacterium or is a non-coding synthetic linker/polylinker sequence. Such a cloning vector is
30 encompassed by the present invention.

Preferably such food grade cloning vectors have a size allowing for the insertion of desirable genes. Accordingly, a suitably sized cloning vector as defined herein has a size which is in the range of 0.5 to 20 kb, although larger
35 vectors may also be used. In preferred embodiments the clon-

ing vector has a size in the range of 1 to 10 kb, such as in the range of 2 to 5 kb. Examples of such cloning vectors are the pFG plasmids as described below.

In accordance with the invention such cloning vectors may be used for insertion of genes coding for desirable gene products, in particular genes isolated from lactic acid bacteria. Such useful genes include genes coding for enzymes which has an advantageous effect on the quality of a food product the manufacturing or preservation of which includes the addition of viable lactic acid bacterial cultures as it has been described above. Thus, such genes inserted into the above cloning vector may code for peptidases, including a dipeptidase, examples of such peptidases being the gene products of the genes *pepN*, *pepC* and *pepR* as exemplified below. Other interesting gene products include lipases, proteases, nucleases and enzymes which are involved in the carbohydrate metabolism of the host bacterium. Inserted genes may also be prokaryotic genes isolated from non-lactic acid bacterial species.

It is furthermore contemplated the useful genes in the present context are eucaryotic genes e.g. mammalian genes coding for immunologically, enzymatically or pharmacologically active gene products, including as an example proteolytic enzymes such as chymosin or plasminogen.

It has been found that a lactic acid bacterium normally coding for a particular enzyme may have the expression of this enzyme increased by a factor of at least 2 such as at least 5 or even by a factor of at least 10 by being transformed with a cloning vector as defined above, in which a gene coding for an enzyme having similar activity, is inserted. Examples of such vectors are the plasmid pFG1 derivatives pFG2, pFG3, pFG4, pFG5 and pFG6 as described in the below examples.

It has been found that the gene product of the suppressor gene of the above food grade vector may in some instances be

"overexpressed" to an extent where the normal growth of the host cell may be impaired. However, it has also been found that mutants may occur in which the natural promoter for the suppressor gene of the vector is mutated, resulting in a
5 decreased suppressor gene expression allowing the host cell to grow normally. In accordance herewith the invention provides in one embodiment a cloning vector comprising a suppressor gene with a promoter functionally linked thereto, in which a mutation occur. It has also been discovered that
10 mutations may occur in a nonsense mutation-containing lactic acid bacterial host cell chromosome which enables the cell when hosting a vector plasmid from which a suppressor gene is overexpressed, to grow normally. Such host cells which apparently are refractory to the effect of the suppressor gene
15 "overproduction" may be very useful hosts for cloning vectors such as e.g. the above pFG1 plasmids and its derivatives.

The lactic acid bacterial culture may comprise any lactic acid bacterium. As used herein, the term "lactic acid bacterium" designates a group of bacteria having as a common
20 characteristic the capability to produce lactic acid from sugars. The majority of the species belonging to this group can be characterized as gram-positive, catalase negative, microaerophilic or anaerobic bacteria which may be cocci or rods. The anaerobic genus *Bifidobacterium* is also generally
25 included in the group of lactic acid bacteria. Accordingly, the pure culture of a lactic acid bacterium preferably comprises bacteria selected from *Lactococcus* spp., *Streptococcus* spp., *Lactobacillus* spp., *Leuconostoc* spp., *Pediococcus* spp. and *Bifidobacterium* spp. In certain useful embodiments, the
30 lactic acid bacterium in the isolated culture is *Lactococcus lactis*.

The culture may, in accordance with the invention, comprise two or more different species of lactic acid bacteria or two or more strains of the same species. As mentioned above, it
35 is common in the production of food products, where lactic acid bacterial starter cultures are used, to apply mixed

cultures, i.e. cultures comprising a multiplicity of strains. As an example hereof it can be mentioned that a mixed culture of *Lactobacillus bulgaricus* and *Streptococcus thermophilus* is typically used in the production of yoghurt. In other dairy products a mixed culture of *Bifidobacterium bifidum* and *Lactobacillus acidophilus* may be used.

In addition to their use as food starter cultures, lactic acid bacteria according to the present invention may also be applied in the production of animal feed such as silage where starter cultures are inoculated in the feed crop to be ensiled in order to obtain a preservation hereof, or in protein rich animal waste products such as slaughtering offal and fish offal, also with the aims of preserving this offal for animal feeding purposes. Yet another significant application of lactic acid bacterial cultures according to the present invention is the use of such cultures as so-called probiotics. By the term "probiotic" is in the present context understood a microbial culture which, when ingested in the form of viable cells by humans or animals, confers an improved health condition, e.g. by suppressing harmful microorganisms in the gastrointestinal tract, by enhancing the immune system or by contributing to the digestion of nutrients.

The culture as defined above may advantageously be in a concentrated form containing e.g. at least 10^9 colony forming units per g of the culture. Such concentrates may be provided as a cell slurry e.g. separated from a fermenter or as a frozen or freeze-dried culture.

In an interesting embodiment, the culture according to the invention comprises a lactic acid bacterium wherein the gene coding for a nonsense suppressor is under the control of a regulatable promoter. As used herein, the term "regulatable promoter" is used to describe a promoter sequence possibly including regulatory sequences for the promoter which promoter is regulatable by one or more factors selected from the

- pH and/or the arginine content of the medium, the growth temperature, a temperature shift eliciting the expression of heat shock genes, the composition of the growth medium including the ionic strength/NaCl content and the growth phase/growth rate of the lactic acid bacterium. Such a regulatable promoter may be the native promoter or it may be an inserted promoter not naturally related to the suppressor gene either isolated from the lactic acid bacterium itself or it may be a heterologous promoter sequence.
- 10 A promoter sequence as defined above may comprise further sequences whereby the promoter becomes regulated by a stochastic event. Such a regulation may e.g. be useful in lactic acid bacterial cultures for which it may be advantageous to have a gradually decreasing activity of the suppressor
- 15 gene under control of the promoter sequence. Such further sequences may e.g. be sequences, the presence of which results in a recombinational excision of the promoter or of genes coding for substances which are positively needed for the promoter function.
- 20 As mentioned above, the invention relates in further aspects to a composition comprising an isolated pure culture of a lactic acid bacterium as defined above, and a microbiologically acceptable carrier and to the use of such a composition as a starter culture in the preparation of a food
- 25 product. It may be preferred that such a composition contains at least 10^9 colony forming units of the bacterium. Preferably, the carrier may comprise nutrients such as an assimilable carbohydrate or a nitrogen source, which can be utilized readily by the lactic acid bacterium. Typically,
- 30 such a composition is provided in the form of a frozen or freeze-dried composition.

As mentioned above, the invention pertains in a further aspect to a plasmid comprising a gene coding for a nonsense suppressor. The gene may in certain preferred embodiments be

35 derived from the chromosome of a lactic acid bacterium. In

accordance with the present invention, the plasmid is constructed by inserting an isolated DNA sequence comprising a suppressor gene which is functional in a lactic acid bacterium, into a starting plasmid capable of replicating in a lactic acid bacterium. The starting plasmid may be one which contains a nonsense mutation, e.g. in a gene the native gene product of which is required for replication of the plasmid or in a gene conferring antibiotic resistance.

The above DNA sequence comprising a suppressor gene is preferably a small sequence such as a sequence in the range of 0.05 to 10 kb, more preferably in the range of 0.1 to 5.1 kb, such as e.g. 3.2, 1.1 or 0.25 kb. The suppressor gene may preferably encode a tRNA with an anticodon recognizing only amber codons, i.e. an amber suppressor. As an example, the DNA sequence coding for such a tRNA may be the following (SEQ ID NO:1):

```
1  GGAGCCATGG CAGAGTGGTA ATGCAACGGA CTCTAAATCC GTCGAACCGT
51 GTAAAGCGGC GCAGGGGTTC AAATCCCCTT GACTCCTTA
```

The plasmid according to the invention may further comprise an inserted gene coding for a desired gene product. In this context, interesting desired gene products include hydrolytic enzymes selected from proteases such as chymosin, peptidases including endopeptidases, lipases, nucleases and carbohydrases; lytic enzymes such as lysozyme or phage lysins; flavour enhancing substances; bacteriocins including nisin, pediocin, and bavaracin; amino acids; organic acids and pharmacologically active substances.

In accordance with the invention, the gene coding for the suppressor which is carried by the plasmid may be under the control of a regulatable promoter as defined above.

As it has been described above, it may be advantageous to confine an extrachromosomal replicon to a particular type of lactic acid bacteria and accordingly, the invention provides

in one aspect a method as defined above of confining an extrachromosomal replicon to a first kind of lactic acid bacterial cells, where the replicon could be naturally transferred to a second kind of lactic acid bacterial cells.

- 5 The first kind of lactic acid bacteria is preferably selected from *Lactococcus* spp. including *Lactococcus lactis*, *Streptococcus* spp., *Lactobacillus* spp., *Leuconostoc* spp., *Pediococcus* spp. and *Bifidobacterium* spp. As used herein, the term "confine" indicates that the replicon is stabilized or con-
- 10 tained in the first kind of cells.

- Nonsense mutated replicons having lost their capability of replication may be derived from plasmids or bacteriophages naturally replicating in lactic acid bacteria. One example of such a non-replicating replicon is a nonsense mutant of the
- 15 citrate plasmid of *Lactococcus lactis* subsp. *lactis* biovar *diacetylactis* strain DB1138 as described above.

- In accordance with the present method, the suppressor-encoding gene may be located on the chromosome or it may be a gene on a replicon such as a plasmid or a bacteriophage which is
- 20 different from the one to be confined to the first kind of cells.

The replicon to be confined may in preferred embodiments be a recombinant replicon comprising a gene coding for a desired gene product as defined above.

- 25 In addition to confining a replicon as it is defined above, it may also be interesting to confine the expression of a desired gene product to a particular kind of lactic acid bacteria by a method where the gene coding for the desired gene product has a nonsense mutation causing the gene product
- 30 not to be expressed. As long as such a replicon is present in a lactic acid bacterial host cell comprising a suppressor gene coding for a product capable of restoring the capability of the nonsense mutated gene to be expressed normally, the gene is expressed. However, if the replicon comprising the

gene coding for the desired gene product escapes from the primary host cell to a second kind of lactic acid bacteria not having a suppressor gene as defined above, then the gene product will not be expressed in that second kind of cells.

- 5 The method of confining a replicon as defined herein is particularly interesting where a mixed culture composition of two or more strains of lactic acid bacteria between which a replicon coding for a desired gene product may be freely transferable, is used e.g. in the production of a food pro-
10 duct as defined above. Thus, the expression of a certain gene product can be confined to one lactic acid bacterial strain in the mixed culture comprising a multiplicity of strains.

- In accordance with the present invention there is also in a further useful embodiment provided a method as defined above
15 of stably maintaining an extrachromosomal replicon, including a plasmid and a bacteriophage, in lactic acid bacterial host cells in a particular environment. In suitable embodiments of the invention, the lactic acid bacterial host cells harbouring the replicon to be stably maintained have a nonsense
20 mutation in one or more genes conferring auxotrophy to the cells whereby the cells have lost their capability to grow in the particular environment due to a lack herein of an essential nutritive substance which cannot be synthesized by the nonsense mutant cells.

- 25 As one example, the nonsense mutation may be one which causes the host cells to lose the capability to grow in a medium which does not contain the precursors for the synthesis in the cells of purine nucleotides. Such auxotrophic mutants are also referred to as Pur⁻ mutants. Milk is such a medium not
30 containing nucleotide precursors in amounts sufficient for growth of such Pur⁻ mutants. Accordingly, the nonsense mutant Pur⁻ lactic acid bacterial host cells will not be able to grow in milk if the replicon to be maintained is lost from the cells. Accordingly, the suppressor gene of the extrachro-
35 mosomal replicon functions as a selective marker for the

lactic acid bacterial host cells. In the present context, the term "a selective marker" is used to designate a genotype which renders lactic acid bacterial cells unable to grow if the replicon to be maintained is lost from the cells.

- 5 It is contemplated that auxotrophic nonsense mutants may, in accordance with the present invention be isolated, which allow an extrachromosomal replicon to be stably maintained in a lactic acid bacterium growing in other specific environments including vegetable products, meat products, bakery
10 products, wines, fruit juices, the gastrointestinal tract, feed crops or offal to be ensiled by a lactic acid bacterium.

It is another interesting aspect of the present invention that it provides a method as defined above of controlling the number of lactic acid bacterial cells in a particular environment allowing growth of lactic acid bacteria. The regulation of the regulatable promoter can be provided as already
15 defined herein.

In one specific embodiment of the above method, the suppressor-encoding gene is regulated so that the expression of
20 the gene is increased causing the lactic acid bacterial cells to grow more slowly or to cease growth, or to die. Such an effect may e.g. be observed where the nonsense mutation is located in a gene coding for a gene product inhibiting the cell growth. As an example of a gene product having an inhibitory effect on growth of lactic acid bacteria may be mentioned a bacteriostatic antibiotic or bacteriocin. The gene product may also be a product such as a lytic enzyme including lysozyme and phage lysins, which is expressible in the
25 bacterium to be controlled, in amounts which inhibits cell growth or causes the cells to die.
30

In another specific embodiment of the present method of controlling the number of lactic acid bacteria, the nonsense suppressor-encoding gene is regulated so that the expression
35 of the gene is decreased or stopped. As one example hereof

the lactic acid bacteria to be controlled are bacteria containing a lysogenic phage and having the nonsense mutation located in a gene selected from a gene coding for a gene product inhibiting the entering of the phage into its lytic cycle whereby, when the expression of the gene coding for the nonsense suppressor is decreased or stopped, the phage enters the lytic cycle, causing the lactic acid bacteria to die. In a further example the bacteria contains a nonsense mutation which is located in a gene coding for a gene product such as a gene involved in the nucleotide synthesis, the expression of which is required for growth of the bacteria, whereby, when the expression of the gene coding for the nonsense suppressor, is decreased or stopped, the gene product which is required for growth of the bacteria is no longer expressed, causing growth of the lactic acid bacterial cells to cease.

LEGENDS TO FIGURES

Figure 1 illustrates the construction of plasmid pFDi10. Filled-in segments indicate DNA from pCI372 or pCI3340, open segments DNA from pVA891 and hatched segments DNA isolated from pCI160; Hi: *HindIII*, E: *EcoRI*, N: *NcoI*, C: *ClaI*, X: *XbaI*, B: *BamHIII*, P: *PvuII*, S: *StuI*.

Figure 2 illustrates the construction of plasmid pAK58;

Figure 3 shows a 300 bp DNA sequence (SEQ ID NO:10) comprising an ochre suppressor gene isolated from the suppressor mutant strain FD100. The potential promoters are indicated with *, marking possible -35 regions and #, marking possible -10 regions. The arrows indicate an inverted repeat forming part of a potential transcription terminator. The underlined bases are expected to be transcribed and modified post-transcriptionally, e.g. by addition of CCA to the 3' end, to form an active tRNA. The start of *Lactococcus* DNA in the plasmids

pFDi17 (nucleotide 121), pFDi18 (nucleotide 121) and pFDi19 (nucleotide 132) is indicated,

Figure 4 shows a 300 bp DNA sequence (SEQ ID NO:11) comprising an amber suppressor gene isolated from the suppressor mutant strain NJ1. The potential promoters are indicated with *, marking possible -35 regions and #, marking possible -10 regions. The arrows indicate an inverted repeat forming part of a potential transcription terminator. The underlined bases are expected to be transcribed and modified post-transcriptionally, e.g. by the addition of CCA to the 3' end, to form an active tRNA,

Figure 5 (A and B) shows the alignment of the FD100 suppressor gene (SEQ ID NO:32) (bottom line) with 20 tRNA-gln genes (SEQ ID NO:12 to SEQ ID NO:31), and

Figure 6 illustrates the construction of pFG1.

Figure 7 illustrates the construction of pAK117.

EXAMPLE 1

The construction of a shuttle plasmid (pFDi10) carrying nonsense mutations in two antibiotic resistance genes

The plasmid pFDi10 was constructed through several steps of selections and clonings. The plasmids involved in these steps are listed in Table 1 and the strains used are listed in Table 2. The individual steps are illustrated in Figure 1 and described in detail below.

In the following, the nonsense mutations in the *erm* and *cat* genes are designated *erm-am* and *cat-am* solely to indicate that the mutations are suppressed by amber suppressors in *E. coli*. No other attempts were made to analyze the type of the nonsense mutations.

Table 1. Plasmids uses for the construction of pFDi10

Plasmid	Host	Antibiotic re- sistance genes	Reference
pVA891	<i>E. coli</i>	<i>cat</i> , <i>erm</i>	Macrina et al. 1983
pCI160	<i>E. coli</i>	<i>tet</i> , <i>bla</i>	Hill et al. 1988
pCI372	<i>E. coli</i> /L. <i>lac-tis</i>	<i>cat</i>	Hayes et al. 1990
pCI3340	<i>E. coli</i> /L. <i>lac-tis</i>	<i>cat</i>	Hayes et al. 1990
pVA89erm-am	<i>E. coli</i>	<i>cat</i> , <i>erm-am</i>	This work
pFDi6	<i>E. coli</i> /L. <i>lac-tis</i>	<i>cat</i> , <i>erm</i>	This work
pFDi6cat-am	<i>E. coli</i> /L. <i>lac-tis</i>	<i>cat-am</i> , <i>erm</i>	This work
pFDi81	<i>E. coli</i> /L. <i>lac-tis</i>	<i>cat</i> , <i>tet</i>	This work
pFDi9	<i>E. coli</i> /L. <i>lac-tis</i>	<i>cat-am</i> , <i>tet</i>	This work
pFDi10	<i>E. coli</i> /L. <i>lac-tis</i>	<i>cat-am</i> , <i>erm-am</i> , <i>tet</i>	This work

Table 2. Strains used in the construction of pFDi10

Strain	Species	Relevant genotype	Reference
MG1363	<i>Lactococcus lac-tis</i>		Gasson 1983
LE30	<i>E. coli</i> K12	<i>mutD</i>	Silhavy et al 1984
R594	<i>E. coli</i> K12	<i>sup</i> ⁰	Campbell 1965
BR2024	<i>E. coli</i> K12	<i>sup</i> ⁰	Austin et al. 1983
BR2025	<i>E. coli</i> K12	<i>supD</i>	Austin et al. 1983
BR2026	<i>E. coli</i> K12	<i>supE</i>	Austin et al. 1983
BR2027	<i>E. coli</i> K12	<i>supF</i>	Austin et al. 1983

1. The construction of pVA891erm-am

The mutator strain LE30 was used to mutagenize pVA891. Competent cells of LE30 were prepared by inoculating LE30 into AB minimal medium (Clark & Maaløe 1967) and allowing growth
5 at 37°C to continue until the OD₆₀₀ was 0.4. The cells were harvested by centrifugation and made competent and subsequently transformed with pVA891 as described by Sambrook et al., 1989. Transformants were selected by plating on LB agar plates supplemented with 10 µg/ml chloramphenicol. Cells
10 from plates containing a total of more than 1000 colonies were pooled by adding 2 ml of LB-broth per plate and resuspending the cells using a bent glass rod. The cells from the suspension were harvested by centrifugation and the plasmids extracted as described in Sambrook et al., 1989.
15 This plasmid preparation was the mutagenized plasmid stock of pVA891.

Strain R594 was transformed with the mutagenized stock of pVA891 and Cm^R transformants selected on LB supplemented with 10 µg/ml chloramphenicol. More than 5x10³ colonies were
20 pooled as described above, and this mixed culture was enriched for erythromycin sensitive mutants by a procedure similar to the enrichment for auxotrophic mutants described by Miller 1972. The enrichment was done by inoculating the mixed culture into 250 ml LB supplemented with 250 µg/ml
25 erythromycin to an OD₆₀₀ of 0.02. After 2 hours incubation at 37°C the OD had increased to 0.1. At this point of time ampicillin was added to a concentration of 50 µg/ml. The culture was incubated further at 37°C for 2 hours. At this time the OD₆₀₀ had decreased to 0.04. The cells were har-
30 vested by centrifugation and washed in AB minimal medium and finally resuspended in AB minimal medium. Dilutions of the resuspended cells were plated on LB + 10 µg/ml chloramphenicol. 300 chloramphenicol resistant colonies were screened for erythromycin sensitivity by streaking on LB +
35 250 µg/ml erythromycin. Out of the 300 colonies tested, 113 were found to be erythromycin sensitive. From these 113

mutants individual overnight cultures were prepared in LB + 10 μ g/ml chloramphenicol. A pool containing 50 μ l of each culture was used for the preparation of plasmids.

This plasmid pool was transformed into BR2024, BR2025 and
5 BR2026, respectively. The transformed cells were plated on LB + 10 μ g/ml chloramphenicol and on LB + 250 μ g/ml erythromycin. Chloramphenicol resistant transformants were obtained with all three strains whereas erythromycin resistant transformants were only obtained with strain BR2026. An
10 erythromycin resistant transformant of BR2026 was purified by streaking to single colonies twice. From this transformant the plasmid pVA891erm-am was isolated.

To verify the presence of an amber mutation, the purified pVA891erm-am plasmid was transformed into BR2024, BR2025 and
15 BR2026, respectively and transformants were selected on LB + 250 μ g/ml erythromycin and on LB + 10 μ g/ml chloramphenicol. The numbers of transformants obtained are listed in table 3. The result shows that pVA891erm-am indeed carries a mutation in the *erm* gene which can be suppressed efficiently by the
20 *supE* amber suppressor and with lesser efficiency by the *supD* amber suppressor.

Table 3. Number of transformants with suppressed pVA891erm-am

	STRAINS					
	BR2024 sup ⁰		BR2025 supD		BR2026 supE	
	cm ^R ery ^R	ery ^R / cm ^R	cm ^R ery ^R	ery ^R / cm ^R	cm ^R ery ^R	ery ^R / cm ^R
Not trans- formed with DNA	2	9	2	4	0	1
5 pVA891erm-am	600	4	1.5x6 ⁻²	255 70	0.3	400 400 1

2. The construction of pFDi6

pFDi6 is a plasmid capable of replicating in *E. coli* as well as in *Lactococcus lactis*. pFDi6 carries two antibiotic resistance markers (*cat* and *erm*). These two markers are expressed well in both hosts.

pFDi6 was constructed by inserting the *erm* gene of pVA891 into the shuttle plasmid pCI3340. This was done by digesting 1 µg of pVA891 DNA simultaneously with the restriction enzymes *Hind*III, *Cla*I and *Pvu*II (*Pvu*II was included to increase the frequency of the desired event, as *Pvu*II does not cleave the fragment carrying the *erm* gene). 1 µg of pCI3340 was digested with the restriction enzymes *Hind*III and *Cla*I. The digested plasmids were mixed, ligated and transformed into R594 as described in Sambrook et al., 1989. Transformants were selected on LB + 10 µg/ml chloramphenicol. 222 chloramphenicol resistant colonies were screened for erythromycin resistance and 24 were found to be resistant to both antibiotics. Plasmid DNA was extracted from 10 of these and all 10 were found to have identical size and structure. One of these was kept as pFDi6.

3. The construction of pFDi6cat-am

A derivative of pFDi6 carrying a nonsense mutation in the *cat* gene was constructed by a method analogous to that used in the construction of pVA891erm-am.

- 5 pFDi6 was transformed into the mutator strain LE30 and transformants selected on LB + 250 μ g/ml erythromycin. More than 10^3 colonies were pooled and plasmid DNA extracted. This stock of mutated pFDi6 DNA was transformed into R594 and transformants selected on LB + 250 μ g/ml erythromycin. More
10 than 10^3 transformants were pooled and used to inoculate 250 ml LB + 10 μ g/ml chloramphenicol to an OD_{600} of 0.03. After growth at 37°C for 2½ hours the OD_{600} had increased to 0.360. At this time ampicillin was added to a final concentration of 50 μ g/ml and incubation continued for an additional 2 hours.
15 At this time the OD_{600} had decreased to 0.09, and the cells were harvested by centrifugation, washed in AB minimal medium, resuspended in AB minimal medium and dilutions were plated on LB + 250 μ g/ml erythromycin. 500 erythromycin resistant colonies were screened for chloramphenicol sensi-
20 tivity and 44 were found to be chloramphenicol sensitive. An overnight culture of each of these 44 mutants was prepared in LB + 250 μ g/ml erythromycin. Plasmid DNA was extracted from a mixture of all 44 cultures. This mixture of mutated plasmids was transformed into BR2024, BR2025, BR2026 and BR2027,
25 respectively.

- Erythromycin resistant transformants were obtained with all four strains whereas chloramphenicol resistant transformants could only be obtained in BR2025, BR2026 and BR2027. One of the chloramphenicol resistant transformants of BR2025 was
30 purified and the plasmid extracted from this transformant was shown to carry pFDi6cat-am by repeating the transformation into BR2024, BR2025, BR2026 and BR2027, respectively. The amber mutation in pFDi6cat-am is suppressed by *supD*, *supE* and *supF*.

4. The construction of pFDi81

The tetracycline resistance gene of pCI160 was chosen for the construction of pFDi81 and subsequently of pFDi9 and pFDi10, as this tetracycline resistance gene is well expressed in
5 *Lactococcus* spp (Hill et al. 1988).

1 μ g of each of the plasmids pCI160 and pCI372 were digested with *Hind*III. The digests were mixed, ligated and transformed into competent cells of R594 as described in Sambrook et al. 1989. Transformants were selected by plating on LB agar
10 supplemented with 10 μ g/ml chloramphenicol. 200 colonies were screened for tetracycline resistance by streaking on LB agar supplemented with 10 μ g/ml tetracycline. 8 colonies were found to carry plasmids with the tetracycline resistance gene inserted in pCI372. One of these was kept and the plasmid
15 designated pFDi81.

5. The construction of pFDi9

pFDi9 is a plasmid of the same structure as pFDi81, but carrying the *cat-am* gene instead of the wildtype *cat* gene. The *Eco*RI-*Stu*I fragment of pFDi81 carrying the *cat* gene was
20 substituted with the *Eco*RI-*Stu*I fragment of pFDi6*cat-am* to construct pFDi9. 1 μ g of pFDi81 DNA was digested with *Eco*RI, *Stu*I and *Nco*I (*Nco*I was included to reduce the frequency of clones carrying the wildtype *cat* gene). 1 μ g of pFDi6*cat-am* was cleaved with *Stu*I + *Eco*RI. The two digests were ligated
25 and transformed into BR2026 (*supE*). Transformants were selected on LB agar supplemented with 10 μ g/ml chloramphenicol and 10 μ g/ml tetracycline.

More than 500 transformants were obtained. Three colonies were purified and plasmid DNA extracted. Transformation into
30 R594 and BR2026, respectively showed that all three plasmids carried the *cat-am* gene as chloramphenicol resistant transformants could be obtained in the *supE* strain BR2026 and not in the non-suppressing strain R594. Tetracycline resistant

transformants were obtained with both strains. One of the three plasmids was kept as pFDi9.

6. The construction of pFDi10

The *erm-am* gene of pVA891*erm-am* was inserted into pFDi9 to
5 give pFDi10.

1 μ g of pVA891*erm-am* was digested with *Xba*I + *Bam*HI + *Eco*RI
(*Eco*RI was included to increase the frequency of the desired
event). 1 μ g of pFDi9 was digested with *Xba*I + *Bam*HI. The two
digests were ligated and transformed into BR2027. Transfor-
10 mants were selected on LB agar supplemented with 10 μ g/ml
tetracycline (LB-tet). 50 colonies were streaked onto LB
plates supplemented with 250 μ g/ml erythromycin (LB-ery) and
onto LB plates supplemented with 10 μ g/ml chloramphenicol
(LB-cam).

15 15 colonies were found to be resistant to all three anti-
biotics. Plasmid DNA was extracted from four of these triple-
resistant transformants, and transformed into R594 and
BR2026, respectively. The transformed cells were plated on
LB-ery, LB-tet and LB-cam, respectively. All of these four
20 plasmids gave tet^R transformants of both strains.
Chloramphenicol resistant transformants were for all four
plasmids only obtained in strain BR2026 which showed that all
four plasmids carried a *cat-am* gene unable to give
chloramphenicol resistance in the non-suppressing strain
25 R594.

Three of the four above plasmids gave erythromycin resistant
transformants of BR2026, but none of R594, and one of the
four plasmids gave erythromycin resistant transformants of
both strains. The latter plasmid was discarded as having a
30 reversion of the *erm-am* gene. One of the three plasmids
having *erm-am*, *cat-am* and *tet* genes was kept as pFDi10.

EXAMPLE 2

Selection of nonsense suppressing strains of *Lactococcus lactis* using pFDi101. Transformation of pFDi10 into *Lactococcus lactis* MG1363

5 Competent cells of MG1363 were prepared and transformed by electroporation as described by Holo and Nes 1989. 10 μ g of pFDi10 was precipitated by ethanol and the dried pellet resuspended in 10 μ l of glass distilled sterile water. 40 μ l competent cells of MG1363 was added and the mixture electro-
10 porated using a BioRad gene pulser using the settings of 25 μ F, 2kv, 200 Ω . The time constant obtained was 4.8. 960 μ l ice-cold SGM17 broth was added and the mixture kept on ice for 5 minutes. The mixture was transferred to a tube containing 2 ml SGM17 broth and incubated at 30°C for 2 hours before
15 dilutions made in SGM17 broth were plated on SGM17 agar plates supplemented with 10 μ g/ml tetracycline. A transformation efficiency of 2×10^5 transformants/ μ g was obtained. One colony was purified by restreaking twice on GM17 agar plates supplemented with 10 μ g/ml tetracycline. The resulting strain
20 FD73 was verified to contain pFDi10 by extracting plasmid DNA as described by Israelsen and Hansen 1993. The plasmid extracted from FD73 had a size identical to pFDi10 and identical restriction pattern when digested with XbaI + BamHI. A sample of FD73 was deposited on 20 September 1993 with DSM-
25 Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig Germany, under the accession number DSM 8557.

A culture of FD73 (MG1363/pFDi10) was prepared by inoculating a single colony of FD73 into 10 ml of GM17 supplemented with
30 10 μ g/ml tetracycline followed by incubation at 30°C for 18 hours. From this overnight culture 0.2 ml was plated on each of the following media: GM17 + 10 μ g/ml tetracycline + 5 μ g/ml chloramphenicol + 1 μ g/ml erythromycin; GM17 + 5 μ g/ml chloramphenicol; GM17 + 1 μ g/ml erythromycin. From a 10^{-5}

dilution of the overnight culture 0.1 ml was plated on GM17 + 10 µg/ml tetracycline. The plates were incubated at 30°C for 42 hours. The results are summarized in Table 4.

Table 4. Cell counts in an overnight culture of FD73

5	Medium	CFU/ml
	tet	1×10^9
	cam	7×10^1
	ery	7×10^0
10	tet + cam + ery	0

The results of this experiment show that neither the cat-am nor the erm-am gene of pFDi10 confer antibiotic resistance to MG1363, indicating that *Lactococcus lactis* MG1363 is not an inherently nonsense suppressing strain. The corresponding
15 wildtype genes are expressed well in MG1363 as the plasmid pFDi6 give erythromycin and chloramphenicol resistance when transformed into MG1363.

2. The isolation of nonsense suppressing mutants of *Lactococcus lactis*.

20 *Lactococcus lactis* FD73 was mutagenized with EMS by the following procedure:

(i) 9 ml of GM17 + 10 µg/ml tetracycline was inoculated with a single colony of FD73 followed by incubation for 18 hours at 30°C;

25 (ii) 270 µl of EMS was added to the above culture and the incubation continued for 100 minutes at 30°C;

(iii) each of 10 tubes of 9 ml GM17 were inoculated with 0.9 ml of the EMS treated culture and subsequently incubated at 30°C for 18 hours;

(iv) from each of the above tubes 0.2 ml was plated onto GM17 plates supplemented with 5 µg/ml chloramphenicol + 1 µg/ml erythromycin. The plates were incubated at 30°C for 42 hours;

(v) one colony from each of the above plates which contained 5 13 to 30 colonies was purified by streaking onto GM17 supplemented with 10µg/ml tetracycline;

(vi) the resistance to chloramphenicol and erythromycin was verified by streaking on GM17 plates with erythromycin and chloramphenicol, respectively;

10 (vii) five colonies showing resistance to *cam*, *erm* and *tet* were selected for further analysis. All five were subsequently shown to be nonsense suppressing strains. In the following description data is only given for one of the five independent mutants. The mutant described in the following is 15 designated FD87.

3. Identification of the localization of the suppressor gene in FD87

Plasmid DNA was extracted from an overnight culture of FD87 in GM17 supplemented with 10 µg/ml tetracycline. The plasmid 20 extracted had, as expected, the same size as pFDi10. The restriction patterns obtained with *Bam*HI and *Hind*III were also identical to the ones obtained with pFDi10.

The plasmid extracted from FD87 was transformed into *E. coli* R594 (non suppressing) and tetracycline resistant transformants 25 selected. The transformants were subsequently screened for resistance to erythromycin and chloramphenicol. All transformants screened were found to be sensitive to erythromycin and chloramphenicol. This result shows that the *cat* and *erm* genes of the plasmid still carry the amber mutation and thereby that the mutational event in FD87 was not a 30 simultaneous reversion of both amber mutations on pFDi10.

FD87 was cured for the pFDi10 plasmid by inoculating 9 ml GM17 with 0.1 ml of a 10^{-6} dilution of a fresh overnight culture of FD87. This culture was incubated for 24 hours at 30°C before plating 0.1 ml of a 10^{-6} dilution of this second
5 culture on a GM17 plate. The plate was incubated at 30°C for 18 hours. 169 colonies appeared on the plate and of these, 100 colonies were screened for resistance to tet, cam and ery by streaking onto GM17, GM17 + tet, GM17 + cam and GM17 + ery, respectively. 97 colonies had retained resistance to all
10 three antibiotics and three colonies were sensitive to all three antibiotics.

One of the sensitive colonies was repurified by streaking on GM17 and this strain was designated FD100. Analysis for plasmid DNA of FD100 did not reveal any plasmids.

15 As the plasmid-cured variant FD100 is sensitive to cat and ery it could be concluded that the mutant FD87 did not acquire alternative antibiotic resistance genes. This strongly indicates that the mutation gave rise to a nonsense suppressor gene. This was proven to be the case by transforming
20 FD100 with pFDi10 and selecting tetracycline resistant transformants as described above for MG1363. The transformants of FD100 were also found to be erythromycin and chloramphenicol resistant, showing that strain FD100 is a nonsense suppressor strain capable of suppressing both amber mutations of pFDi10
25 whereas the parent strain MG1363 is unable to suppress any of these two amber mutations of pFDi10.

A sample of FD100 was deposited on 20 September 1993 with DSM-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig Germany under
30 the accession number DSM 8561.

EXAMPLE 3

Cloning of the suppressor gene from FD1001. The construction of the cloning vector pFDi3

pFDi3 is an *E.coli-Lactococcus lactis* shuttle vector carrying
5 a cat gene and an erm-am gene.

pFDi3 was constructed by cloning the erm-am gene of
pVA891erm-am into pCI372. This cloning was done by digesting
pVA891erm-am DNA with *Xba*I + *Bam*HI + *Pvu*II and digesting
pCI372 with *Xba*I + *Bam*HI as described in Example 1 for the
10 construction of pFDi10.

When pFDi3 is transformed into *Lactococcus lactis* MG1363 only
chloramphenicol resistant transformants are obtained as
MG1363 is unable to suppress the erm-am mutation.

This vector was used for the cloning of the nonsense sup-
15 pressor gene of FD100 in MG1363 as it was expected that the
cloning of the suppressor gene into pFDi3 would give a
plasmid expressing erythromycin resistance in MG1363.

2. Cloning of the suppressor gene

Chromosomal DNA of FD100 was prepared from a fresh 100 ml
20 overnight culture of the strain grown in GM17. The cells were
harvested by centrifugation at 7000 x g for 10 minutes. The
cells were resuspended in TE buffer and harvested by
centrifugation. The cell pellet was frozen and kept at -20°C
for 18 hours.

25 The pellet was thawed and resuspended in 3 ml STET buffer [8%
w/v Sucrose, 5% v/v TritonX100, 50 mM EDTA (pH 8.0), 50 mM
TrisCl (pH 8.0)]. 750 µl 10 mg/ml of lysozyme was added, and
the mixture was incubated at 37°C for 60 minutes. 750 µl 10%
w/v SDS was added and incubation continued at 37°C for 30
30 minutes followed by incubation at 65°C for 30 minutes.

The solution was extracted with phenol:chloroform (1:1) three times. DNA was precipitated by adding NaCl to a final concentration of 0.5M and adding an equal volume of isopropanol. The precipitated DNA was wound around an inoculation loop, washed three times in 70% ethanol and resuspended in 500 μ l TE-buffer. The DNA concentration was determined to be 1.8 μ g/ μ l by measuring the absorbance at 260 nm.

3.5 μ g chromosomal FD100 DNA was digested with *Hind*III. 12 μ g pFDi3 DNA was digested with *Hind*III and treated with Calf Intestine Alkaline Phosphatase (Boehringer Mannheim) as described in Sambrook et al. 1989. The two mixtures were extracted with phenol and precipitated with ethanol and ligated as described in Sambrook et al. 1989. The ligated DNA was precipitated with ethanol and dissolved in 20 μ l sterile distilled water and electroporated into *Lactococcus lactis* MG1363 as described by Holo and Nes 1989.

Transformants were selected on SGM17 supplemented with 1 μ g/ml erythromycin and on SGM17 supplemented with 5 μ g/ml chloramphenicol. The transformation efficiencies obtained were 20 erythromycin resistant transformants per μ g DNA and more than 10^5 chloramphenicol resistant transformants per μ g DNA. A total of 241 erythromycin resistant transformants were obtained.

Plasmid DNA was prepared from 11 erythromycin resistant transformants. The plasmids were digested with *Hind*III and analyzed by electrophoresis on an 0.8% agarose gel. All of these 11 plasmids had acquired a 3.2 kb fragment. Two of the plasmids had also acquired other fragments.

Restriction analysis using *Hind*II revealed the presence of a *Hind*II site in the 3.2 kb *Hind*III fragment. The *Hind*II digests also revealed that the nine clones carrying only a single new fragment all had the fragment in the same orientation relative to the vector. In order also to isolate clones with the opposite orientation we isolated plasmid DNA from an

additional 20 transformants and found plasmids with the 3.2 kb *HindIII* fragment in the opposite orientation. pFDi11 is one of the plasmids with only a single new *HindIII* fragment of 3.2 kb and pFDi12 is a plasmid with the same 3.2 kb fragment inserted in the opposite orientation.

EXAMPLE 4A

The construction of a plasmid with an amber nonsense mutation in the replication region

Four primers were synthesized for use in polymerase chain reaction synthesis of the desired DNA fragment. These had the following sequences:

Primer 1 (SEQ ID NO:2): 5' TGAATTCAGAGGTTTGATGACTTTGACC 3'
Primer 4 (SEQ ID NO:3): 5' GGAATTCCTAACAAAAGACTATTAACGC 3'
Amber 1 (SEQ ID NO:4): 5' AAACCTCTAGAGCAAGTATTCC 3'
15 Amber 2 (SEQ ID NO:5): 5' CTTGCTCTAGAGTTTTTGTAG 3'

Primer 1 corresponds to nucleotides 610-621 and Primer 4 is complementary to nucleotides 2340-2361 of the citrate plasmid replication region (Jahns et al, 1991). Both primers contain *EcoRI* sites at their 5' end. Amber 1 and Amber 2 each contains two mismatches that introduce an amber codon in the coding sequence (SEQ ID NO:7) and create an *XbaI* site as shown in Table 5 below:

EXAMPLE 4B

The isolation of a MG1363 strain suppressing the amber mutation in pAK58

Electroporation of pAK58 into MG1363 was done following
5 standard procedures (Holo & Nes, 1989). As expected, pAK58
was unable to replicate in MG1363. Under conditions where a
replicating citrate plasmid produced about 200,000 transformants,
pAK58 yielded two. These two colonies were further
analyzed and one was found to contain an intact pAK58 while
10 the other contained no plasmid. The strain containing pAK58
was named NJ1/pAK58 and saved for further analysis.

A sample of NJ1/pAK58 was deposited on 20 September 1993 with
DSM-Deutsche Sammlung von Mikroorganismen und Zellkulturen
GmbH, Mascheroder Weg 1b, D-38124 Braunschweig Germany under
15 the accession number DSM 8559.

Plasmid pAK58 was cured from NJ1/pAK58 by growing 30 generations without antibiotics. After plating and testing, 16%
of the colonies tested were found to be free of pAK58. One of
these was named NJ1 and further characterized.
20 Electroporation of NJ1 with pAK58 yielded a high frequency of
transformants, indicating that NJ1 contains a suppressor
mutation allowing replication of pAK58 in spite of the amber
mutation. This suppressor suppressed neither the nonsense
mutations in pFDi10 nor the nonsense mutations in the phage
25 ϕ MPC100 derivatives (see Example 5). Thus this suppressor is
different from the FD100 suppressor described hereinbefore.

EXAMPLE 4C

Cloning of the nonsense mutation suppressor gene from NJ1

Total genomic DNA was isolated from NJ1 following standard
30 procedures (Johansen & Kibenich, 1992) and partially digested

with *Sau3A* I. These fragments were ligated with *Bgl*III digested pAK58 and transformations of MG1363 were done. A DNA fragment of NJ1 containing the suppressor gene will allow replication of pAK58 in MG1363. One such clone was obtained and designated pAK85. The 5.1 kb of DNA of pAK85 was subcloned in pCI372 (Hayes et al, 1990) in a variety of ways and tested for suppression of the amber mutation in pAK58 by electroporation of MG1363 with a mixture of the pCI372 derivative to be tested and pAK58. One clone, pAK89.1, contains a 1.1 kb *Eco*RI-*Xba*I fragment and has suppressor activity. Sequencing of pAK89.1 has been done and revealed the suppressor gene to be a tRNA with an anticodon recognizing only amber codons. Thus, the suppressor is an amber suppressor. The DNA sequence coding for this tRNA is the following (SEQ ID NO:1):

```
1  GGAGCCATGG CAGAGTGGTA ATGCAACGGA CTCTAAATCC GTCGAACCGT
51 GTAAAGCGGC GCAGGGGTTC AAATCCCCTT GACTCCTTA
```

The final three base pairs are expected to be replaced with CCA posttranscriptionally.

Homology searches of the EMBL DNA sequence data bank, release 34.0 revealed that this tRNA most likely is a serine tRNA. The DNA sequence of the wild-type tRNA gene in MG1363 was determined by PCR amplifying a 450 bp sequence containing this gene, followed by sequencing of the amplified fragment. The tRNA gene mutated in NJ1 was confirmed to be a serine tRNA gene with the anticodon 5' CGA 3' in the wild type and 5' CTA 3' in the mutant.

A sample of MG1363/pAK85 was deposited on 20 September 1993 with DSM-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig Germany, under the accession number DSM 8558.

EXAMPLE 5

The isolation of nonsense mutants of the prolate headed
lactococcal phage ϕ MPC100

ϕ MPC100 is a prolate *Lactococcus* phage from the phage collection of Chr. Hansen's Laboratorium A/S. This phage gives large plaques (diameter 2-4 mm) when plated on MG1363. This phage was used for the isolation of mutants with nonsense mutations in genes essential for phage development. Such mutants will be unable to form plaques on MG1363, but capable of growing on FD100.

A phage stock of ϕ MPC100 with a titre of 1.8×10^{10} plaque forming units (PFU)/ml was used for the preparation of a mutagenized phage stock. The mutagenesis was done using hydroxylamine treatment of the phage stock as described in Silhavy et al. 1984. The hydroxylamine treatment of ϕ MPC100 for 22 hours reduced the titre with the same order of magnitude as described for *E. coli* phages. The survival rate for ϕ MPC100 was 3×10^{-3} .

Dilutions of the mutated phage stock was plated for plaques on strain FD100 by mixing 10 μ l of phage dilution, 200 μ l of a fresh overnight culture of FD100 in GM17 supplemented with 10mM CaCl_2 and 10 mM MgSO_4 and 3 ml M17 of soft agar supplemented with 10 mM CaCl_2 and 10 mM MgSO_4 . (The soft agar had been melted by boiling and cooled to 42°C.)

The mixture was poured onto a GM17 agar plate and incubated at 30°C for 18 hours. On the plate with mutagenized phages plaques of normal size as well as small plaques were observed. 81 plaques were isolated by removing agar plugs containing a plaque with a sterile Pasteur pipette. The agar plugs were transferred to 200 μ l M17 + 10 mM CaCl_2 + 10 mM MgSO_4 and phages allowed to diffuse out of the agar for 2 hours at 8°C.

15 μ l of each of the 81 phage stocks were spotted onto two plates with lawns of FD100 and MG1363, respectively. Three of the 81 phages were found to grow only on FD100 whereas the remainder grew equally well on both strains.

- 5 The three mutant phages which were designated ϕ MPC100a12, ϕ MPC100a16 and ϕ MPC199a77 were purified by plating to single plaques twice on strain FD100. On FD100 the mutant ϕ MPC100a77 gives small plaques and the two others give plaques of normal size. A sample of ϕ MPC100a77 was deposited on 20 September
10 1993 with DSM-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig Germany under the accession number DSM 8562.

The reversion frequencies of the three phage mutants were determined by titration of phage stocks on the permissive
15 host FD100 and on the nonpermissive host MG1363.

Table 6. Reversion frequencies of ϕ MPC100 nonsense mutants

	Titre (PFU/ml) on:		Reversion frequency
	FD100	MG1363	
ϕ MPC100a12	1.5×10^6	0.6×10^2	4×10^{-5}
ϕ MPC100a16	4.8×10^6	$9 \cdot 10^2$	2×10^{-4}
ϕ MPC100a77	8.7×10^6	7×10^2	8×10^{-5}

- 20 To verify that the phage mutations are suppressed in FD100 by the same suppressor as the *erm-am* mutation used for the selection of FD100 it was examined if the phage mutants were able to grow on MG1363 with pFDi11 or pFDi12.

It was found that introduction of either pFDi11 or pFDi12
25 makes MG1363 a permissive host for the phage mutants above. It can thus be concluded that the suppressor cloned in pFDi11 and pFDi12 is capable of suppressing the *erm-am* mutation as

well as the phage mutations. This proves that the phage mutants are nonsense mutants.

EXAMPLE 6

Determination of the size of the suppressor gene of FD100

- 5 Since a suppressor tRNA gene is smaller than 100 bp it was aimed at determining the location of the suppressor gene on the 3.2 kb fragment inserted in pFDi11 and pFDi12.

From pFDi11 a total of 3.7 kb was deleted thereby removing the *erm-am* gene and 2.2 kb of the inserted fragment. The
10 resulting plasmid pFDi13 retains 1.0 kb of the original insert. From pFDi12 a total of 2.5 kb was deleted thereby removing the *erm-am* gene and 1.0 kb of the inserted fragment. The resulting plasmid pFDi14 retains 2.2 kb of the original insert.

- 15 pFDi13 and pFDi14 were constructed by digesting pFDi11 and pFDi12 respectively with *Hind*III. The digested DNAs were extracted with phenol, precipitated and ligated (separately). The ligation mixtures were transformed into R594 as described in Sambrook et al. 1989. Selection of transformants were made
20 on LB supplemented with 10 µg/ml chloramphenicol.

Three transformants from each experiment were analyzed. All three transformants from the pFDi11 experiment were identical and one was kept as pFDi13. All three from the pFDi12 experiment were identical and one was kept as pFDi14.

- 25 pFDi13 and pFDi14 were transformed into MG1363 by electroporation selecting for chloramphenicol resistant transformants.

The presence or absence of the suppressor gene on pFDi13 and pFDi14 was determined by testing for suppression of the phage mutant ϕ MPC100a12. The results are given in Table 7.

Table 7. Suppression of nonsense mutations of ϕ MPC100a12

Strain	Growth of ϕ MPC100a12
MG1363	-
FD100	+
MG1363 pFDi11	+
MG1363 pFDi12	+
MG1363 pFDi13	-
MG1363 pFDi14	+

5
10 These results show that the suppressor is carried on the 2.2 kb fragment of pFDi14.

15 In order to determine the location of the suppressor gene even more precisely deletions were made in the plasmid pFDi14 using the Erase-a-Base system from Promega. The Erase-a-Base system generates unidirectional deletions in a plasmid by
20 using ExonucleaseIII. The deletions are forced to be unidirectional by linearizing the plasmid with two restriction enzymes of which one is generating 3' overhangs (ExonucleaseIII resistant). 5 μ g pFDi14 DNA was digested with *Sac*I (ExonucleaseIII resistant 3' overhangs) and *Bam*HI (ExonucleaseIII sensitive 5' overhangs). The treatment with
25 ExonucleaseIII at 30°C, sampling with intervals of 1 minute from 1 to 15 minutes after addition of ExonucleaseIII, treatment with S1 nuclease, treatment with Klenow fragment of DNA polymerase and ligation were done exactly as described in the Erase-a-Base manual from Promega.

Each of the ligated samples were transformed into *Lactococcus lactis* MG1363 by electroporation. Transformants were selected on SGM17 agar supplemented with 10 μ g/ml of chloramphenicol. Transformants were obtained from every sample. 20 colonies
30 from each of the five last samples (expected to carry the largest deletions) were tested for suppression of ϕ MPC100a12.

Of the 100 colonies tested only five retained the suppressor (2 from the 12 minutes sample, 2 from the 14 minutes sample and 1 from the 15 minutes sample).

5 Plasmid DNA was extracted from several suppressing and non-suppressing transformants. The two smallest plasmids still having the suppressor were named pFDi17 and pFDi18. The largest plasmid (although smaller than pFDi17 and pFDi18) not carrying a suppressor was pFDi19.

10 The length of the chromosomal insert was found to be 266 bp for pFDi17 and pFDi18. The fragment retained in pFDi19 was 11 bp shorter (see Example 7).

EXAMPLE 7

Nucleotide sequence of the nonsense suppressor gene of FD100

15 The DNA sequence of the insert derived from FD100 in each of the three plasmids pFDi17, pFDi18 and pFDi19 was determined using the sequenase kit from USB, Cleveland, Ohio, USA. The protocol supplied with the kit for sequencing double stranded plasmids was followed. For each plasmid the sequence of both strands was determined. The sequence of one strand was deter-
20 mined using the primer 5' GCTAGAGTAAGTAGTT 3' (primer # 1206 from New England Biolabs, Beverly, Massachusetts, USA) (SEQ ID NO:8), the sequence of the other strand was determined using the primer 5' CCTTTACCTTGTCTACAAACC 3' (SEQ ID NO:9).

25 pFDi17 and pFDi18 contained fragments with the same length and sequence. pFDi19, which did not express suppressor activity contained a fragment which was found to be 11 bp shorter than the fragment in pFDi17 and pFDi18 (cf. Figure 3).

30 The sequence of the fragment carrying the suppressor gene was compared to all nucleotide sequences present in the EMBL-database release 34 using the Fasta program of the GCG pro-

gram package (Devereux et al. 1984, Nucleic Acids Research, 12, 387-395). The sequence showing the highest homology to the sequence of Figure 3 was the sequence of tRNA-gln of *Bacillus subtilis*. 19 other tRNA-gln genes from bacteria, chloroplasts and mitochondria also showed extremely high homologies.

The alignment of the FD100 suppressor gene with 20 tRNA-gln genes is presented in Figure 5. This shows that the suppressor gene is a tRNA-gln gene. At the position of the anticodon the FD100 suppressor tRNA-gln has the triplet 3' ATT 5' instead of the usual gln anticodons 3' GTT 5' or 3' GTC 5'. This shows that the suppressor tRNA-gln is an ochre suppressor recognizing the stop codon 5' UAA 3' as a gln codon. However, this ochre suppressor does also recognize the amber stop codon 5' UAG 3' (cf. Example 5) probably due to wobble basepairing at the third position of the codon.

Sequencing of the wild type gene has subsequently revealed that this gene is a tRNA-gln gene with the anticodon 3' GTT 5'. Sequencing of this tRNA-gln allele from the suppressor mutants described in Example 2 revealed that not all suppressor mutants were of this type. It is therefore expected that further analyses of the other mutants will reveal suppressors with other specificity.

The 11 extra basepairs in pFDi17 and pFDi18 compared to pFDi19 contain a sequence resembling the -35 part of a consensus promoter. The suppressor gene of pFDi19 is not expressed, probably due to the lack of a promoter. The plasmid pFDi19 may assumingly be used to construct suppressor genes with regulated or altered expression.

EXAMPLE 8

Isolation of purine auxotrophic mutants and suppression of two mutations in *Lactococcus lactis* located in pur genes, by a nonsense suppressor gene.

- 5 *Lactococcus lactis* purine auxotrophic mutants were isolated. Introduction of a nonsense suppressor gene into *Lactococcus lactis* pur mutants resulted in prototrophy.

In general, the *de novo* synthesis of purine nucleotides from small precursors requires 10 enzymatic reactions leading to
10 inosine monophosphate (IMP). IMP is used in the synthesis of both AMP and GMP. Purine bases, originating intracellularly or from exogenous sources, and nucleosides are converted to nucleotides via salvage pathways which have been shown to be distinct among different organisms (for reviews see: Nygaard
15 1983; Neuhaard and Nygaard 1987). Virtually nothing is known about the purine metabolism in the anaerobic gram-positive bacterium *Lactococcus lactis* (Nilsson and Lauridsen, 1992). In the following is described the isolation of purine auxotrophic mutants and how they can be used in combination with
20 suppressor genes.

1. Materials and methods

1a. Bacterial strains and media used.

The plasmid-free *Lactococcus lactis* strain MG1363 (Gasson, 1983) was grown in M17 medium (Oxoid) or in a defined medium
25 having the same composition as the phosphate-buffered minimal medium of Clark and Maaløe (1967) except that the NaCl of this medium was replaced by the same weight of sodium acetate (DN-medium). As carbon source in M17 medium or DN medium 0.5% glucose was used. For selection purposes, chloramphenicol 5
30 mg/L of medium was used. Purine compounds as supplements were added, when appropriate in the following concentrations:

adenine, hypoxanthine, guanine and xanthine, 15 mg/mL;
adenosine, inosine and guanosine 30 mg/L.

1b. Isolation of purine auxotrophic *Lactococcus lactis* strains.

- 5 MG1363 was grown overnight in M17 medium. 1/33 vol ethyl methane sulphonate (EMS, Merck) was added and the culture incubated further 2 1/2 hours at 30°C. The culture was divided and diluted 50 fold in fresh DN-medium containing hypoxanthine to give five cultures which were subsequently grown
10 overnight. DN-medium containing hypoxanthine was inoculated with mutagenized culture to 2×10^7 bacteria/ml and grown to 8×10^7 bacteria/ml. The cells were harvested, washed twice in DN medium without hypoxanthine and resuspended to 4×10^6 bacteria/ml in DN medium and incubated for 2 hours at 30°C.
15 Ampicillin was added to a final concentration of 100 µg/ml and the culture was further incubated for 5 hours. The cells were harvested by filtration (Millipore, size 0.2 µm), washed 3 times with DN medium, and suspended in 1/10 vol DN medium containing hypoxanthine. 50 µl culture (2×10^4 viable
20 bacteria/ml) was spread onto DN hypoxanthine-containing agar plates and incubated overnight. 582 colonies from each culture were screened for growth with and without hypoxanthine on DN-medium agar plates.

1c. DNA manipulation.

- 25 *Lactococcus lactis* plasmid DNA was isolated according to the method of Johansen and Kibenich (1992). *Lactococcus lactis* was transformed by electroporation as recommended by Holo and Nes (1989). The *Lactococcus lactis* plasmids pFDi17 and pFDi19 as described above were used.

30 2. Isolation of purine auxotroph mutants

Five mutants (DN207-211) of strain MG1363 with a purine auxotrophic phenotype was isolated as described above in

materials and methods. Exogenously supplied adenine, hypoxanthine, xanthine, guanine or the ribonucleosides adenosine, inosine and guanosine, restored growth of DN207-211.

3. Suppression of pur mutations in DN207-211 by the nonsense
5 suppressor gene.

The two plasmids pFDi17 (*sup+*) in which an ochre suppressor is expressed, and pFDi19 (*sup-*) not expressing a suppressor, were transformed into the DN207-DN211 strains followed by selecting for chloramphenicol resistance on M17 agar plates.
10 Transformants were screened for growth with and without hypoxanthine on DN medium agar plates. The plasmid pFDi17 (*sup+*) could transform DN209 and DN210 to Pur⁺, whereas pFDi19 (*sup-*) could not. In all the other strains none of the plasmids could transform the cells to Pur⁺. This shows that
15 the mutations causing the purine auxotrophic phenotypes in DN209 and DN210 were nonsense mutations.

These experiments have shown that it is possible to isolate auxotrophic mutants in *Lactococcus lactis* (here purine auxotrophic mutants are used as a model system) and to screen
20 these for nonsense mutations that can be restored by introducing suppressor genes into the cells. The significance of these findings is that such a system may be used for maintenance of plasmids (like pFDi17) e.g. during fermentation in media that do not support growth of the auxotrophic mutants
25 unless the auxotrophy is restored by a plasmid containing a suppressor gene. The advantage may be to use one and the same suppressor gene for suppression of amber/ochre nonsense mutations located in a variety of distinct genes of *Lactococcus lactis* strains.

30 The one and same suppressor gene may also be used to control expression of various gene products, as in the example with the *pur* gene products in the strains DN209 and DN210. In

these strains, the *pur* gene products are only expressed if the suppressor gene is introduced into the cells.

A sample of DN209/pFDi17 was deposited on 20 September 1993 with DSM-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig Germany
5 under the accession number DSM 8560.

4. Stability of pFDi17 in *Lactococcus lactis* strain DN209

Cultures of *Lactococcus lactis* strain DN209 containing pFDi17 (*sup*+) or pFDi19 (*sup*-) were grown for about 100 generations
10 in 9.5% LAB-milk (9.5% skim milk powder in water) containing 0.5% purine-free casamino acids as the basal medium. A culture of DN209/pFDi19 and one culture of DN209/pFDi17 was grown in the basal medium supplemented with 15 mg/l of hypoxanthine as a purine source, and one culture of DN209/pFDi17
15 was grown in the basal medium only.

DN209/pFDi19 cannot grow in milk not containing a purine source, but by adding a purine source it may be possible to observe losses of the plasmid during growth. DN209/pFDi17 was capable of growing in the basal medium supplemented with the
20 purine source as well as in the basal medium without such supplementation. Under these experimental conditions, no losses of plasmids were observed in any of the DN209/pFDi17 cultures or in the DN209/pFDi19 culture.

EXAMPLE 9

25 Strategy for the provision of nonsense suppressing *Leuconostoc* spp

It is suggested that *Leuconostoc* spp comprising a nonsense suppressor-encoding gene may be provided by carrying out the following experiments:

In a first step it is determined which of commonly used replicons can be used to transform *Leuconostoc* spp. including *Leuconostoc lactis* and *Leuconostoc cremoris* e.g. by electroporation of competent cells. Replicons to be tested include
5 the citrate plasmid replicon (pKR46), the pCI305 replicon (pCI3340) and the pSH71 replicon (pNZ18). If the citrate plasmid replicon works, pAK58 may be used to isolate suppressors; if the pCI305 replicon works, pFDi10 can be used to select suppressors. If none of the suggested replicons work,
10 a new selection plasmid must be constructed e.g. as outlined in the following.

The chloramphenicol resistance gene from pNZ18 is eliminated and replaced with the tetracycline resistance gene and the ery-am and cam-am markers from pFDi10. It is contemplated
15 that the easiest way to achieve this would be to clone the 3.2 kb *Bgl*III fragment from pNZ18, containing the replication origin, into the *Bgl*III or *Bam*HI site of pFDi10. This requires that the pCI305 and pSH71 origins can coexist on the same plasmid. If this is not the case, the pCI305 replicon may be
20 inactivated by digesting with *Pac*I, flushing the ends with DNA polymerase and ligating. This will introduce a -2 frameshift into the *repB* gene.

In a subsequent step an amber suppressor *Leuconostoc* spp may be selected by introducing the new plasmid into e.g. *Leuconostoc lactis* DB1164 or *Leuconostoc cremoris* DB1165 and
25 selecting for tetracycline resistance followed by selecting mutants which are simultaneously resistant to erythromycin and chloramphenicol (following mutagenesis, if necessary), curing any interesting plasmid and confirming the antibiotic
30 resistance is lost and reintroducing the selection plasmid and confirming that antibiotic resistance is regained. This will only occur if suppression is occurring.

EXAMPLE 10

The construction of pFG1, a food grade cloning vector1. Introduction

In order to use genetically manipulated microorganisms in food products, vectors that are derived totally from the organism to be manipulated are desirable. A useful vector contains a replication region, a selectable marker and a multiple cloning site allowing insertion of desirable genes. In addition, it should be small enough to allow insertion of desired DNA without difficulty.

A food-grade cloning vector, pFG1 replicating in lactic acid bacteria was constructed which is based totally on DNA sequences from *Lactococcus*, and synthetic sequences. pFG1 contains the replication region of the *Lactococcus lactis* subsp. *lactis* biovar *diacetylactis* citrate plasmid, the ochre suppressor tRNA gene from *L. lactis* strain FD100 allowing selection of transformants of *Lactococcus lactis* DN209 (Example 8), and a synthetic polylinker with 11 unique restriction sites, identical to that found in vector pIC19R (Marsh et al., 1984).

The usefulness of pFG1 was demonstrated by cloning the *pepN* gene from *Lactococcus lactis* ssp. *cremoris* Wg2 (Strömman, 1992) to obtain the plasmid pFG2. A strain containing pFG2 contains 4-5-fold as much lysine aminopeptidase activity as the same strain containing only pFG1, and pFG2 is the first member in a new line of genetically manipulated lactic acid bacterial flavor control cultures.

2. Bacterial strains, plasmids and media

MG1363 is a plasmid-free derivative of *Lactococcus lactis* strain NCDO 712 (Gasson, 1983). FD100 is a mutant of MG1363 containing an ochre suppressor. DN209 is a purine auxotroph

of MG1363, suppressible by the ochre suppressor. Wg2 is a wild-type strain of *Lactococcus lactis* ssp. *cremoris*. *Escherichia coli* DH5 α was used for some cloning steps.

The cloning vector pIC19H [ampicillin resistance; Amp^R] (Marsh et al., 1984) was used throughout. The construction of the food-grade vector and cloning of the *pepN* gene are described below.

Lactococcus strains were grown at 30°C in minimal medium (Recipe 053 of Genetics Department, Chr. Hansen's Laboratory) containing 1% M17. *E. coli* strains were grown in LB medium at 37°C. Ampicillin was used at 50 μ g/ml. Lysine-aminopeptidase activity was assayed using the standard procedure of Chr. Hansen's Laboratory (Analytical Procedure P-019).

15 3. Plasmid preparations and transformations

Plasmid DNA for sequencing and electroporations was prepared with the Qiagen plasmid kit (Diagen, Dusseldorf, Germany). Small scale plasmid preparations from *Lactococcus* were done according to Recipe 039 of Genetics Department, Chr. Hansen's Laboratory. Plasmids were introduced into *Lactococcus* by electroporation of glycine-grown competent cells (Holo and Nes, 1989, Recipe 018 of Genetics Department, Chr. Hansen's Laboratory).

4. Construction of the food-grade cloning vector pFG1

25 4.1. Cloning of the citrate plasmid replication region

Polymerase chain reaction (PCR) was done with two primers designed to amplify the entire replication region of the citrate plasmid as a 1.7 kb fragment. The primers had *EcoRI* sites at the 5' end and the resulting fragment was cloned into pIC19H to give pKR41 (Fig. 6). This clone has been described previously (Pedersen et al., 1994).

The replicon comprises the origin of replication and the *repB* gene of the citrate plasmid of *L. lactis* subsp. *lactis* biovar *diacetylactis*. Flanking sequences totalling 300 bp from the same plasmid are also included as are two synthetic linkers
5 which contribute a total of 6 bp to this fragment.

4.2. Cloning of the ochre suppressor gene

The selectable marker is the *supB* gene of *L. lactis* strain FD100. This DNA fragment is 208 bp and has a sequence iden-
10 tical to that found in FD100 except for the presence of two linkers contributing a total of 6 bp.

The ochre suppressor gene of strain FD100 has been cloned and is contained on a plasmid called pFDi18 (Example 6). PCR using two primers (Ochre-1, CGAATTCATAAATGCTTTCCCTATTC (SEQ
15 ID NO:33); and Ochre-2, CGAATTCTTGAAATTTATGAGGGTTTTTGG (SEQ ID NO:34)) on pFDi18 resulted in a 208 bp *EcoRI* fragment containing the ochre suppressor gene. This fragment was cloned into pIC19H to give pAK95 (Fig. 6).

4.3. Combining the replication region with the suppressor 20 gene

Plasmids pKR41 and pAK95 were digested with *EcoRI*, mixed, ligated and used to electroporate DN209, selecting on minimal medium. Transformants with plasmids containing at least the citrate plasmid replication region and the suppressor gene
25 will form colonies. Some recombinant plasmids will also contain pIC19H. Colonies were scraped off the selection plates and plasmids extracted. Plasmids in this pool containing pIC19H were obtained by transforming DH5 α , selecting amp^R colonies.

30 Analysis of plasmids from seven amp^R transformants revealed that all had pIC19H, the 1.7 kb *EcoRI* fragment from pKR41 and the 208 bp *EcoRI* fragment from pAK95. This was expected because the double selection used will give only plasmids

containing all three fragments. One clone was saved as pAK102 (Fig. 6).

4.4. Deletion of the nonfood-grade components of pAK102

The final step in the construction of the food-grade cloning vector was the elimination from pAK102, of all of pIC19H except for the multiple cloning site. This was done by digesting with *Hind*III, self ligating and electroporating DN209 on minimal medium. All 20 colonies analyzed had the desired plasmid. One strain was saved and deposited in the culture collection as CHCC3061. The plasmid contained in this strain was named pFG1 and is the food-grade vector. pFG1 has a total size of 2003 bp

The multiple cloning site (polylinker) is identical to that in a vector called pIC19R (Marsh et al., 1984) and is shown below (SEQ ID NO:35). The polylinker is 69 bp and was synthesized totally *in vitro* by Marsh et al. (1984). All sites are unique except for *Eco*RI and *Cla*I.

					H									
					i									
E		B			n			B		E		E		
c	S	a	S	P	d	N	XS	g	X	c	C	c		
o	m	m	a	s	I	r	ha	l	b	o	l	o		
R	a	H	l	t	I	u	oc	I	a	R	a	R		
I	I	I	I	I	I	I	II	I	I	V	I	I		

GAATTCCCGGGGATCCGTCGACCTGCAGCCAAGCTTTCGCGAGCTCGAGATCTAGATATCGATGAATTC
 1 -----+-----+-----+-----+-----+-----+-----+-----+----- 69
 CTTAAGGGCCCTAGGCAGCTGGACGTCGGTTCGAAAGCGCTCGAGCTCTAGATCTATAGCTACTTAAG

The selectable marker can, so far, only be used in DN209 which is a derivative of MG1363. MG1363 is a plasmid-free derivative of NCDO 712 and is therefor Lac⁻ and Prt⁻. In order to use pFG1 in other lactic acid bacterial strains, mutations suppressible by the ochre suppressor will be

needed. Preferred mutations will be in genes in purine or pyrimidine biosynthesis because milk does not contain sufficient amounts of these compounds to support the growth of such mutants, thus making milk a selective medium for the mutants. Such mutants can be isolated by mutagenesis and enrichment techniques currently in use in the Department of Genetics of Chr. Hansens' Laboratorium. Plasmids constructed using DN209 can then be easily transferred into these mutants, resulting in new genetically manipulated lactic acid bacterial strains, including *Lactococcus* strains useful for a variety of cultures.

The DNA sequence of pFG1 (SEQ ID NO:36) is shown below:

```

1   GAATTCCTCGG GGATCCGTCG ACCTGCAGCC AAGCTTTTCGC GAGCTCGAGA
51  TCTAGATATC GATGAATTCC TAACAAAAGA CTATTAACGC TTAATTCCTC
15 101 ATTTTTTCTT GTCGATTTTC GGTCCGTTGA ACTTTTTTTTA TTTTGTAG
151 TCTTTTTTTT ATAAACTTTT GTTCTTCAAG GTTTAGGACG ATCGAACCAC
201 TATTGTTTTT TTGTCGATTT TCGGTCGGCA AAAACTTTAA ATGGTATTGA
251 ACGGTCTGTT TAGCTAGTCC TAGCTCGTCC GCCAACTCTT TTATCGTTTT
301 TAAGTCTTCA CTCATGGTTT AAGTCCTGCC TTTTAACCGT TGGCAGATAT
20 351 TGTTCAATGG CTTTTTTAAG ATATTTTCGCT ACATTACGTT TAGAATAGGC
401 TTCTTTTTTG CTGGCAACAT AAGACAAGTG GTCTTTGACA CCATTTAGCC
451 CTCTTAATTC TTTCAGTTTC TCATAAAGCG GATAAACATT CTTCTGTAAG
501 CCTACCATTG TGGCTGTATC CATAATATCA TTCATGCCAA TTAAGAAATT
551 TTCAGATAAA AGTCTTGTAT ATTTACTTTC CATTGCCTGT TTTAGTAAGT
25 601 CAGCTTCATT TCTTGATTTT TGCTTTTTAT CGTCTTGATA GTCTTTATCT
651 CCCAACTTGT AACTGTTATC GTCTGCCATG CGTTTCTTCT CAATATGAAA
701 GACAATAGAG TCAATGCTCC GCCCTGCTTT CTTTTTCTCA TAGGTTACAT
751 TAAAAGAGGT GTGAGCGTTG ATTTCTTCAA TTGCTTTTTT TAATACTCTA
801 GTTTCAAAAT GGGGAAAATG TTGATGTTCA TTTATTGTAT CAGTTATTTT
30 851 TCGCAATTCT TTCACTTTTA TTGAGGGGTT GCGGTAGGAT TCCACTTGTT
901 CAACTCTCCG TCCCCCTTTC ACGCTGTAAT GTTCGTATTG GTTATAATTC
951 ATGGATAACC AACGATACAA AATAATCGAA TACTTGCTAT TGAGTTTTTG
1001 TAGTTCGGAA ATTTTATATT GAGTAAATTC TGCCTTTAAA TCAATCAGAT
1051 AGGGCATAAT GGCTTGGTCA AAACGTATTG TTACTTCATC GTTATAATCG
35 1101 TTCCATTTTA CATAAGGAAT AGGCACAATG CTTTCATACT CAATACCTAG

```

1151 TTTCTTATCA GCTTTAATAT TGAAAAAGGC TTGCTTTTGC ATATAATTAA
 1201 CTGCTTCTTT GAATTGACTA TGCTTACTGC TAGACGATAC TTCAAAAAAT
 1251 TTAAAAAGTT CAGATTTTAA AAGATAAACA GTATTATTTT TTGGGGGTTT
 1301 TTCGGTATCA ATACAAGACA CGGCTAACTC AAACATTTTT AAAGCTGTTT
 5 1351 TTTGCATTTT AGCCACACTT TGAATTAAAG CGTTATGCTC CACTACTTTG
 1401 CGTTTTTCTA ATTCATTCAA GGTGAGCACC TGCTTTTGTT TGTTTTGTTT
 1451 TTCTGGTATA ATCATAGTAT AAATACGCTC CTTTGCGTGT TTTAGTAGTA
 1501 GCATAGAGAA AGTCATTTCA TAGTGAGTTT TCTCTATGCT TTTATTATAC
 1551 TATATACAGT ACACAAATAC AAAAGTCGTG CTGTGTACAT CGATTTTTGT
 10 1601 GACTCTATAC ATCGATTTTT GTGACTCTAT ACATCGATTT TTGTGACTGT
 1651 TTAATTTCTA TAACTAGCGA AAACACTGCC TTTTTTTTCA CGCAAAAGAA
 1701 CAAAAGATTA AAATATATAT GATAAATATA TAGTAGGCTT CGCCTTTTTT
 1751 TATTTTTTTC AAAAATTTAA AACCAAAGGT CAAAGTCATC AAACCTCTGA
 1801 ATTCTTGAAA TTTATGAGGG TTTTGGTAA AATATTTCTT GTCGTCATCA
 15 1851 AGCGATCTTG GGTATAGCC AAGCGTAAG GCAAGGGACT TTAACCCCT
 1901 CATGCGTTGG TTCGAATCCA GCTACCCAG TAAAAAACT TTAAAGGAAA
 1951 CGTTGTTTCC TTTTTTCTTT TACTAAAAT ATGATAGAAT AGGGGAAAGC
 2001 ATTTAT

A strain of DN209/pFG1 was deposited on 6 May 1994 under
 20 accession No. DSM 9190 with DSM-Deutsche Sammlung von Mikro-
 organismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124
 Braunschweig Germany.

EXAMPLE 11

25 Demonstration of the usefulness of pFG1 as a food-grade cloning vector

A 3.5 kb *Bam*HI/*Sac*I fragment containing the entire *pepN* gene
 (also referred to as *lap* gene), coding for a lysine-aminopep-
 tidase was moved from plasmid pST03 (Strøman, 1992) into the
 multiple cloning site of pFG1 to produce a plasmid named
 30 pFG2. The transformed strain DN209/pFG2 was added to the
 culture collection of Chr. Hansen's Laboratorium under the
 name CHCC3062 and deposited on 6 May 1994 under accession No.
 DSM 9191 with DSM-Deutsche Sammlung von Mikroorganismen und
 Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig
 35 Germany.

Cell free extracts were prepared from DN209/pFG1 and DN209/pFG2 and assayed for lysine-aminopeptidase. Enzyme activity in DN209/pFG2 was 228.3 nmoles/min/mg protein which was 4-5 fold higher than for DN209/pFG1 (48.7 nmoles/min/mg protein). Thus, introducing extra copies of the *pepN* gene into DN209 results in increased expression of that gene.

€

EXAMPLE 12

Stability of pFG-derived plasmids in milk

The β -galactosidase gene from *Leuconostoc mesenteroides* subsp. *cremoris* was inserted into pFG1 to produce pFG3. This gene was obtained from a clone named pSB1 (Johansen and Kibenich, 1992a) which has been shown by DNA sequence analysis to contain the *lacL* and *lacM* genes (unpublished data). Cells containing this plasmid give blue colonies on plates containing X-gal while plasmid-free cells give white colonies. This gives a simple method for detecting plasmid loss and allows screening of many colonies for determining the stability of this plasmid.

DN209/pFG3 was grown in GM17 or in milk and plated at various times on X-gal-containing plates. Milk was supplemented with glucose and casamino acids because DN209 is plasmid free and therefor Lac^- and Prt^- . The percent white colonies at various times was determined and is presented below:

5

10

White colonies	Milk + glucose + casamino acids	GM17
0 Generations	0.1%	0.1%
10 Generations	0.4%	0.5%
20 Generations	0.1%	13.1%
30 Generations	0.1%	8.8%
40 Generations	0.2%	3.4%

These results clearly demonstrate that milk is a selective medium for strains containing pFG1 derivatives, in this case pFG3. Satisfactory stability was also obtained with GM17. The decrease in percent white colonies after 20 generations is believed to be due to the accumulation of faster growing variants of DN209/pFG3.

EXAMPLE 13

20 Isolation and characterization of faster-growing variants of DN209/pFG1

During the course of stability studies with DN209/pFG3 as described in Example 12 above, it was noticed that faster growing variants of the strain appeared to accumulate. Analysis of these variants revealed a mutation in the tRNA structural gene which would destabilize the tRNA resulting in reduced expression of the suppressor gene. Testing of DN209/pFG1 revealed the same accumulation of faster growing variants.

DN209/pFG1 was grown 45 generations in GM17, then plated on GM17 plates. Large colonies were patched to Minimal medium to identify those which had retained pFG1. Twelve mutants were isolated from a single culture. Plasmid analysis revealed that all had pFG1 and that one mutant (#12) had a reduced plasmid copy number. DNA sequence analysis of the suppressor tRNA gene revealed three classes of mutants. One class had no apparent alterations. One class had a GC to CG transversion in the promoter region while the other had a TA to CG transition (SEQ ID NO:37). Both of these are in or near the region postulated to be involved in the stringent response (Ogasawara et al., 1983, Nilsson and Johansen, 1994) and would be expected to decrease suppressor gene expression. These are illustrated below:

15			C in pFG1.2
	Mutants		Cin pFG1.1
	Wild-type	<u>CTTGAAATTTATGAGGGTTTTTGTA</u> <u>AAATATTTCTTGTCGTCATCA</u>	
		-35	-10 Stringent

20 The mutant plasmids described here could be used as the second generation food-grade vector as they have overcome a potential problem with pFG1 (i.e. a slight growth inhibition).

25 The class of mutants with no apparent alterations in plasmid copy number or in the suppressor gene are particularly interesting because they might contain chromosomal mutations overcoming the growth inhibition caused by pFG1. To confirm that they do not contain plasmid alterations, we electroporated DN209 with pFG1, pFG1.1 and the plasmid containing no detectable alterations (called pFG1.3).

Streaking of the resulting transformants revealed that cells containing pFG1.1 produced faster growing colonies than cells containing pFG1 and pFG1.3. Thus, a plasmid mutation is responsible for the better growth of DN209/pFG1.1, and pFG1.3

does not contain such a mutation. Clearly then, the mutation giving faster growth of the original 'DN209'/pFG1.3 must be in the DN209 chromosome. The plasmid was cured from 'DN209'/pFG1.3 resulting in a strain named GH209 which we expect to be a better host for pFG1 and the various derivatives as a chromosomal mutation in this strain overcomes the slight growth inhibition caused by pFG1.

EXAMPLE 14

The construction of a pFG-derivative expressing a lactococcal lysyl-, alanyl-, histidyl-amino peptidase (PEPC)

A 2.3 kb gene coding for lysyl-, alanyl-, histidyl-amino peptidase (*pepC*) was isolated from *Lactococcus lactis* strain CHCC377 (Chr. Hansen's Laboratory's culture collection).

1. Cloning and characterization of the *pepC* gene

The *pepC* gene was cloned by PCR technique. The complete nucleotide (nt) sequence of the *pepC* gene has been determined (see below) and an open reading frame (ORF) of 1308 nt is predicted to encode a polypeptide of 436 amino acids (aa) (approx. 52 kDa; pI 5.92). The 5'-flanking region contains no hydrophobic sequence encoding a potential leader sequence suggesting an intracellular localization of PEPC like all aminopeptidases so far known in *Lactococcus*. A consensus promoter and elements (-35, -10, and SD) that are involved in transcription and in the initiation of translation in *Lactococcus* are present. The gene also contains an inverted repeat downstream from the TAA stop-codon, which might be involved in termination of transcription.

Sequence homology was found with the proteolytic enzymes of the cysteine proteinase family (enzymes with an active thiol group), which includes papain, aleurain and cathepsins B and

H. No (significant) homology was found between PEPC and papain outside the regions encoding the active site.

The *pepC* gene is not (over-)expressed in *E. coli* as e.g. *pepN*, when a plasmid (pUC18) harbouring the *pepC* gene is transformed into *E. coli* strain DH5 α . No enzyme activity could be measured and no extra or "heavier" band in the 50 kDa region could be detected after acrylamide gel-electrophoresis, when compared to a control strain without the gene fragment. Whether this is due to the assay procedure employed or is caused by a non-functional *pepC* promoter in *E. coli*, is not known at present.

The sequence comprising *pepC* is shown below (SEQ ID NO:38:

```

1      ATGACAGTAA CATCAGATTT CACACAAAAA CTCTACGAAA ATTTTGCAGA
51     AAATACAAAA TTGCGTGCGG TGGAAAATGC CGTGACTAAA AATGGTTTGC
15 101   TTTCATCACT CGAAGTCCGT GGTTCACATG CAGCAAATTT GCCTGAGTTT
151    TCAATTGACT TGACAAAAGA CCCTGTAACG AATCAAAAAC AATCTGGTCG
201    TTGCTGGATG TTTGCTGCTT TGAACACTTT CCGTCATAAA TTTATCAATG
251    AATTTAAAC  AGAGGATTTT GAGTTTTTAC AAGCTTACAC TTTCTTCTGG
301    GATAAATATG AAAAATCAAA CTGGTTCATG GAACAAATTA TTGGTGATAT
20 351    TGAAATGGAC GATCGTCGTT TGAAATTCCT TTTACAAACA CCACAACAAG
401    ATGGCGGCCA ATGGGATATG ATGGTTGCAA TTTTGTAAAA ATATGGAATT
451    GTTCCCAAAG CTGTTTATCC TGAATCACAA GCTTCAAGTA GCTCACGTGA
501    ATTGAATCAA TACTTGAATA AACTACTCCG TCAAGATGCT GAAATTTTGC
551    GTTATACAAT TGAGCAAGGT GGAGATGTTC AAGCAGTTAA AGAAGAAGTT
25 601    TTGCAAGAAG TCTTTAATTT CCTTGCGGTA ACTTTAGGTT TGCCACCACA
651    AAATTTTGAA TTTGCTTTCC GTAATAAAGA TAATGAATAC AAAAAATTTG
701    TTGGTAGTCC AAAAGAATTT TACAATGAAT ATGTTGGAAT TGATTTGAAT
751    AATTATGTGT CAGTAATCAA TGCTCCAAC TCTGACAAAC CTTATAATAA
801    GAGCTACACA GTTGAGTTTC TTGGAAATGT TGTGCGTGGT AAAGAAGTGA
30 851    AACATTTGAA TGTTGAAATG GACCGCTTTA AAAAAATTGGT CATTGCCCAA
901    ATGCAAGCTG GTGAAACAGT TTGGTTTGGT TGTGACGTGG GTCAAGAATC
951    AAATCGTTCA GCAGGACTTT TGACAATGGA TTCTTATGAT TTCAAATCTT
1001   CATTGATAT  TGAATTTACT CAAAGCAAAG CAGGACGTCT TGACTATGGT
1051   GAGTCGTTGA TGACGCATGC CATGGTTTTA GCGGGTGTGG ATTTAGATGC
35 1101  TGACGGAAAT TCAACTAAAT GGAAAGTTGA AAATTCATGG GGTAAAGATG

```


1151 CGGGTCAAAA AGGATATTTT GTTGCCTCTG ATGAATGGAT GGATGAATAT
1201 ACTTATCAAA TTGTTGTCCG TAAAGACCTT TTAAGTGAAG AAGAATTGGC
1251 TGCTTACGAA GAGAAACCTC AAGTACTTCT ACCATGGGAC CCAATGGGTG
1301 CTTTAGCTTA A

5 2. Construction and characterization of a pFG-derivative
containing the CHCC377 *pepC* gene

The CHCC377 *pepC* gene was inserted into the polylinker of pFG1 to obtain pFG4. DN209 was transformed with this plasmid and the peptidase activity of DN209/pFG4 was compared with
10 that of DN209/pFG1 (control). The PEPC activity of the control was 3.1 nmoles/min/mg protein but that of DN209/pFG4 was 12.5 nmoles/min/mg protein, i.e. about a 4-fold increase of activity.

15 A strain of DN209/pFG4 was deposited on 6 May 1994 under accession No. DSM 9192 with DSM-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig Germany.

EXAMPLE 15

20

Construction of pFG derivatives containing the dipeptidase gene (*pepR*) from *Lactococcus* strain NCDO712.

A *Hind*III fragment of 2.3 kb which overlaps the 5' end of the *pepR* gene was cloned and characterized by sequencing. The
25 fragment codes for a polypeptide (PEPR) of 471 amino acids of about 52 kDa. The gene was cloned in plasmid pUC18 and it was found that the gene product was not overproduced in *E. coli* and it was confirmed that the gene product is a dipeptidase. In the following the gene is referred to as *pepR* and the gene
30 product as PEPR. Below is shown a 1419 bp sequence comprising the *pepR* sequence (SEQ ID NO:39):

```

1   ATGACAAC TA TTGATTTTAA AGCTGAAGTT GAAAAGCGTA AGGACGCTTT
51  GATGGAAGAT TTGTTTAGCC TTTTGCGCAT TGATTCTGCA ATGGATATGG
101 AACATGCAGA TGCTGAAAAT CCATTTGGCC CTGGTCCAAG AAAAGCTTTG
151 GATGCATTCT TGAAAATTGC CGAACGTGAT GGTATACAA CTAAAAATTA
5   201 TGATAACTAT GTTGGACATT TTGAATATGA AAACGGAGCA AATGCTGATG
251 CCGAAGTTCT CGGAATTATT GGTCACTTAG ATGTTGTTCC TGCTGGTTCC
301 GGTGGGATT CAAATCCATT TGAGCCAGAA ATCCGTAATG GGAATCTCTA
351 TGCTCGTGGT GCTTCTGATG ATAAAGGACC AACAGTTGCA TGTTACTATG
401 CACTCAAATT TTTGAAAGAA CTTAATCTTC CATTATCTAA AAAAATCCGT
10  451 TTCATCGTTG GTACAAACGA AGAAACAGGT TGGGCAGATA TGGATTACTA
501 CTTTGAGCAC TGTGAATTGC CGTTGCCTGA TTTTGGTTTC TCACCTGATG
551 CTGAGTTCCC AATTATCAAT GGTGAAAAG GGAATATCAC AGAATATCTC
601 CATTTCTCAG GTAAAAATGC TGGTCAAGTT GTTCTTCACA GCTTTAAAGC
651 AGGTCTTGCA GAAAATATGG TTCCAGAATC AGCAACTGCA GTGATTTTCA
15  701 GTGCTAAAGA TTTAGAAGCT GCACTTGAAA AATTTGTAGC TGAACATGCA
751 AGCAAAAATC TTCGTTTTGA CCTTGAAGAG GCTGATGGAA AAGCAACAAT
801 TACGCTTTAT GGTAAATCAG CGCATGGTGC GATGCCAGAA AAAGGGATTA
851 ATGGAGCAAC TTATCTTACT TTGTTCTTGA ATCAATTTGA CTTTGCTGAC
901 GGTGCTGCTG CCTTCATTAA AGTTGGGGCT GAAAAAATT CTTGAAGATCA
20  951 TGAAGGTGAA AAATTAGGAA CAGCTTTTAT TGATGAATTG AAGGGAAATA
1001 CCTCAATGAA TGCTGGTGTT TGGTCATTTG ATGAAAATGG TGAAGGTAAA
1051 ATCGCCCTCA ATTTCCGTTT CCCACAAGGG AACAGCCCAG AGCGTATGCA
1101 AGAAATTCTT GCTAAACTTG ATGGGGTTGT TGAAGTTGAA CTTTCAAAAC
1151 ACCTCCACAC ACCTCACTAT GTTCCAATGT CAGACCCACT TGTATCAAGA
25  1201 TTGATTGATG TTTATGAAAA ACACACTGGT CTTAAAGGCT ATGAAACAAT
1251 CATTGGTGGT GGAACTTTCG GTCGTCTGTT GGAACGTGGT GTTGCTTATG
1301 GAGCAATGTT TGAAGGAGAA CCAGATTCAA TGCACCAAGC GAATGAAATG
1351 AAACCTGTTG AGAATATCTA CAAAGCGGCA GTGATTTATG CTGAAGCAAT
1401 TTATGAACTT GCAAAATAA

```

30 New plasmids pFG5 and pFG6 were constructed by inserting the above 2.3 kb fragment into pFG1, in either directions.

A strain of DN209/pFG5 and of DN209/pFG6 were deposited on 6 May 1994 under accession Nos. DSM 9193 and DSM 9194, respectively, with DSM-Deutsche Sammlung von Mikroorganismen und
 35 Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig Germany.

EXAMPLE 16

Control of gene expression and of growth in lactic acid bacteria by regulated suppression of a rep-am mutation.

The experiments described in this Example illustrate how
5 regulation of the expression of a suppressor gene can be utilized to control expression from other genes. This control of gene expression is further extended to controlling the growth of lactic acid bacteria in different environments.

1. Bacterial strains and growth media

10 The Pur⁻ mutant strain *Lactococcus lactis* DN209 pur-am as described in the above Example 8 was used as host for various plasmids. The media used were M17 medium supplemented with 0.5% glucose (GM17) or the purine-free DN-medium based on the phosphate-buffered medium of Clark and Maaløe (1967). When
15 required, antibiotics were added to the following final concentrations: chloramphenicol, 10 mg/l and erythromycin 2 mg/l. The purine compounds adenine, hypoxanthine and guanosine were added to a final concentration of 15 mg/l as described in the results.

20 2. Plasmids

The plasmids pFDi17 (sup+) (Example 6) expressing an ochre suppressor, pFDi19 (sup-) (Example 6) not expressing a suppressor and pAK58 rep-am (Example 4) containing an amber mutation in the replication essential gene *repB* are described
25 above.

For the experiments with regulated expression of the *sup* gene, the plasmid, pIAM4 was constructed in the following manner: pFDi19 contains a nonsense suppressor gene that is silent (no expression), because the *sup* gene lacks a promoter
30 to direct expression. Inserting a promoter in front of the *sup* gene restores expression. However, the expression from

the promoter located in front of the *purD* gene of *Lactococcus lactis* is regulated. Expression from this promoter is dependent on the accessibility of purines. If purines are available in the growth medium, expression from this promoter is repressed. However, if purines are not present in the medium the expression is derepressed. Therefore, this *purD* promoter was selected to direct the expression of the *sup* gene of pFDi19. A 850 bp *EcoRI* fragment that contains the *Lactococcus lactis purD* promoter was cloned into a unique *EcoRI* site of pFDi19 which is located just in front of the *sup* gene of pFDi19.

3. Construction of the experimental strains

The DN209 strain was transformed with the plasmids pFDi17 (*sup*+), pFDi19 (*sup*-) and pIAM4 (*P_{pur}sup*) and transformants were selected for chloramphenicol resistance. The strains DN209/pFDi17 and DN209/pFDi19 were constructed and used as experimental control strains.

4. Results

The three strains DN209/pFDi17, DN209/pFDi19 and DN209/pIAM4 represent strains with differently expressed suppressor genes. DN209/pFDi17 contains the wildtype *sup* gene that is expressed more or less constitutively when grown in DN-medium with and without purines. DN209/pFDi19 contains a suppressor gene that is not expressed because the gene lacks a promoter. However, DN209/pIAM4 contains a suppressor gene that is only expressed in media without purine compounds whereas no or only minor expression of the suppressor gene is observed in media containing purines. This can be used to control the replication of the plasmid pAK58 that contains an amber mutation in the replication essential gene *repB*. The replication of pAK58 is therefore dependent on suppression of the amber mutation in the *repB* gene. If pAK58 is capable of replicating in a host strain, this strain becomes erythromycin resistant.

In the below Table 8 are shown the results of attempts to introduce pAK58 into the above-mentioned strains DN209/pFDi17, DN209/pFDi19 or DN209/pIAM4 (P_{pur}^{sup}). When grown on DN-medium agar plates without purines but containing erythromycin, no transformants were obtained with DN209/pFDi19 (sup^-), whereas transformants could be obtained with both DN209/pFDi17 (sup^+) and DN209/pIAM4 (P_{pur}^{sup}). This is in accordance with the fact that pAK58 cannot exist in host strains without a suppressor gene. However, as it can be seen, only DN209/pFDi17/pAK58 and not DN209/pIAM4/pAK58 was able to grow on media containing erythromycin and purines (DN supplemented with adenine (ad), hypoxanthine (hx) and guanosine (gu), or GM17). This is in accordance with the assumption that the suppressor gene in DN209/pIAM4 is not expressed on media containing purines and accordingly, pAK58 cannot replicate and accordingly, no erythromycin resistant transformants were obtained.

This experiment demonstrates regulated suppression, not only regulation of the expression of the suppressor gene but also regulated expression of other genes dependent on suppression and also regulation of the growth of host bacteria.

Table 8. Selection of DN209 strains in which transformation with pAK58 is attempted

Strain	Number of transformants with 50 ng pAK58 selecting Ery ^R and Cam ^R on different media		
	DN	DN+ ad, hx, gu	GM17
DN209/pFDi17	> 10 ³	> 10 ³	500
DN209/pFDi19	0	0	0
DN209/pIAM4	> 10 ³	0	0

EXAMPLE 17

Construction of an amber mutation located in an essential gene.

The *ftsH* gene of *Escherichia coli* is essential for growth. A
5 gene encoding a membrane protein with putative ATPase activity which is homologous to this essential *Escherichia coli* protein, FtsH was identified adjacent to the *hpt* gene and the *trnA* operon in *Lactococcus lactis* (Nilsson et al., 1994). The deduced amino acid sequence of this gene product showed full-
10 length similarity to FtsH protein of *Escherichia coli*.

Introducing an amber mutation in this essential gene of a *Lactococcus lactis* strain will result in a strain the viability of which will depend on the expression of the suppressor gene. Accordingly, an amber mutation was introduced by polymerase-chain reaction (PCR) into codon 325 of the *Lactococcus*
15 *lactis ftsH* gene and this mutant gene with its flanking regions has been cloned into the integration vector pV2 (Nilsson et al., 1994). Introducing this amber mutation into the chromosome of *Lactococcus lactis* will result in a strain
20 where maintenance of a suppressor gene is essential on all media. Furthermore, the growth of such a strain can be controlled with regulated suppression as it is explained in Example 16.

EXAMPLE 18

25 Procedure for selecting lactic acid bacterial mutants which are not capable of growth in milk

Mutagenesis of *Lactococcus lactis* strain CHCC2281 was performed by treating a 10 ml outgrown culture in M17 medium with 300 μ l EMS (Sigma #M0880) for 2.5h at 30°C.

The mutagenized culture was distributed into ten test tubes and 10 ml M17 medium was added to each tube and growth allowed to continue at 30°C for 18h.

From each of the ten cultures 1.5 ml was used to inoculate 30 ml M17 medium and growth allowed to continue at 30°C until OD at 600 nm (OD_{600}) was between 0.2 and 0.3 when cells from 1.0 ml of each culture were harvested by centrifugation, washed twice in 0.9% sterile NaCl solution and resuspended in 20 ml milk.

- 10 The ten cultures in milk were incubated at 30°C for 2h. Ampicillin was then added at a concentration of 100 μ g/ml to each and incubation continued for 5h at 30°C. 2 units of penicillinase (Sigma #P0389) was added to each culture and incubation continued for 30 minutes. Dilutions were plated on
15 M17 agar plates to obtain single colonies, and the plates were incubated at 30°C.

- Colonies were screened for the ability to grow on milk agar plates. 200 colonies from each of the enriched cultures were screened and the number of mutants unable to grow on milk
20 agar was between 10 and 40. All enrichments produced mutants with the desired phenotype.

- All mutants except one was subsequently found to be *lac*⁻ mutants as they were able to grow on milk agar plates supplemented with glucose. Presumably, the *lac*⁻ mutants result from
25 the loss of the plasmid carrying the *lac* genes.

The one mutant strain which was unable to grow on milk + glucose agar plates was not suppressed to the wildtype by introduction of the plasmid pFD118 and accordingly the mutation was not a nonsense mutation.

- 30 However, desired nonsense mutants can be isolated if the enrichment for *lac*⁻ strains is avoided. This can easily be achieved by the addition of glucose to the milk used in the

enrichment cultures and on the milk agar plates. If milk is substituted by milk + glucose in the enrichment medium, the above procedure will exclusively yield mutants of the same class as the one unable to grow on milk + glucose. Screening
5 of a collection of this type of mutants will (as screening of *pur*⁻ mutants) yield some mutants which can be suppressed by the cloned suppressor gene.

Accordingly, it is contemplated that the above selection procedure, when modified as indicated by enriching the muta-
10 ted culture in a medium containing milk and glucose, will provide the appropriate means for effectively selecting lactic acid bacterial mutant strains which as a result of nonsense mutation has lost the capability of growing in milk. Such strains will be useful as the basis for constructing, in
15 accordance with the present invention, lactic acid bacterial strains which can be contained to milk.

EXAMPLE 19

Providing a derivative of pFDi10 which is capable of repli- cating in a *Leuconostoc* species

20 In order to demonstrate the generality of the herein disclosed techniques in lactic acid bacteria a derivative of pFDi10 (Example 1) was constructed which can be used in members of the *Leuconostoc* genus, a lactic acid bacterial genus which is fairly distantly related to *Lactococcus*. This
25 construction procedure includes identification of a *Leuconostoc* plasmid replicon, addition of that replicon to pFDi10 and introducing this derivative into *Leuconostoc*. It is contemplated that such an approach is suitable for any plasmid-containing lactic acid bacterium.

1. Identification of a *Leuconostoc* replicon

Leuconostoc mesenteroides subsp. *cremoris* DB1165 contains 4 plasmids (Johansen and Kibenich, 1992). Two of these plasmids contain a single *Bgl*III site allowing the cloning of the entire plasmid as a *Bgl*III fragment. Cloning was into the *Bgl*III site in the polylinker of pIC19H (Marsh et al., 1984). pBL1 contains the 8.3 kb plasmid from DB1165 and pBL2 contains the 3.6 kb plasmid cloned in pIC19H. A 2.2 kb *Bam*HI-*Cla*I fragment from pVA891 (Macrina et al., 1983) containing the *Ery*^R gene was inserted into pBL1 and pBL2 to give pAK109 and pAK110, respectively.

Lactococcus lactis strain MG1363, *Leuconostoc lactis* strain DB1164, *Leuconostoc cremoris* strain DB 1165 were electroporated with pAK109 and pAK110. Colonies were obtained in two electroporations and MG1363/pAK109 and DB1164/pAK109 were purified and the presence of pAK109 was confirmed by plasmid analysis. Thus, pAK109 replicates in *E. coli*, *Lactococcus lactis* and *Leuconostoc lactis*, and the *Bgl*III site of the 8.3 kb plasmid can be used for cloning without interference with replication.

2. Construction of pFDi10 derivatives which can replicate in *Leuconostoc* spp.

The polylinker of pFDi10 contains a unique *Bam*HI site. The above 8.3 kb plasmid was inserted into that site as a *Bam*HI fragment producing two clones, pAK116 and pAK117, differing only with regard to the orientation of the inserted DNA fragment. Thus, these plasmids contain all of the pFDi10 (i.e. including replicons for *E. coli* and *Lactococcus*, a gene for tetracycline resistance and nonsense mutations in genes for resistance to chloramphenicol and erythromycin) and a replicon which is functional in *Leuconostoc* spp. These plasmids have a size of about 20.5 kb (Fig. 7).

3. Strategy for introduction of pAK116 or pAK117 into *Leuconostoc* spp.

Attempts to introduce pAK116 or pAK117 into *Leuconostoc lactis* DB1164 or *Leuconostoc mesenteroides* subsp. *cremoris* DB1165 by electroporation were unsuccessful, presumably due to the size of this plasmid and the low efficiency of electroporation of *Leuconostoc*.

However it is known (David et al., 1989; Dessart et al., 1991) that *Leuconostoc* spp. can be successfully transformed and accordingly, it is contemplated that transformants of *Leuconostoc* spp. such as those mentioned above, containing pAK116 or pAK117 can be obtained by mating MG1363/pAK116 or MG1363/pAK117 (which can be constructed by electroporation) with DB1164 or DB 1165 and selecting for resistance to vancomycin (200 µg/ml) and tetracycline (10 µg/ml). DB1164 and DB 1165, like other dairy *Leuconostoc* strains are inherently resistant to vancomycin, whilst MG1363/pAK116 and MG1363/pAK117 are sensitive to that antibiotic. Resistance to tetracycline is conferred by pAK116 or pAK117.

It is contemplated that the above pFDi10 derivatives can form the basis for selecting *Leuconostoc* species carrying suppressor genes by using essentially the same procedures as detailed in Example 2 including guidance from standard microbiological methods which are well-known to those skilled in the art.

REFERENCES

1. Andachi Y., F. Yamao, A. Muto and S. Osawa 1989: Codon recognition patterns as deduced from sequences of the complete set of transfer RNA species in *Mycoplasma capricolum*.
5 J. Mol. Biol. **209**, 37-54.
2. Austin and Wierzhicki 1983. Plasmid **10**, 73-81.
3. Campbell, A. 1965: The steric effect in lysogenization by bacteriophage lambda. I. Lysogenisation by a partially diploid strain of *E. coli* K12. Virology **27**, 329.
- 10 4. Clark, D.J. and O. Maaløe 1967: DNA replication and the division cycle in *Escherichia coli*. J. Mol. Biol. **23**, 99-112.
5. David, S., G. Simons and W.M. Vos 1989: Plasmid transformation by electroporation of *Leuconostoc paramesenteroides* and its use in molecular cloning. Appl. Environ. Microbiol.
15 **55**, 1483-1489.
6. Demerec, M., E.A. Adelberg, A.J. Clark and P.E. Hartman 1966: A proposal for a uniform nomenclature in bacterial genetics. Genetics **54**, 61-76.
7. Dessart, S.R. and L.R. Steenson 1991: High frequency
20 intergeneric and intrageneric conjugal transfer of drug resistance plasmids in *Leuconostoc mesenteroides* ssp. *cremoris*. J. Dairy Sci. **74**, 2912-2919.
8. Deno H. and M. Sugiura 1983: The nucleotide sequence of tRNA Ser (GCU) and tRNA (UUG) genes from tobacco chloroplasts. Nucleic Acids Res. **11**, 8407-8414.
25
9. Eggertson, G. and D. Söll 1988: Transfer ribonucleic acid-mediated suppression of termination codons in *Escherichia coli*. Microbiol. Rev., **52**, 354-374.

10. Gasson, M.J. 1983: Plasmid complements of *Streptococcus lactis* NCD0712 and other lactis streptococci after protoplast induced curing. J. Bacteriol. **154**, 1-9.
11. Hanic-Joyce, P.J. and M.W. Gray 1990: Processing of
5 transfer RNA precursors in a wheat mitochondrial extract. J. Biol. Chem. **265**, 13782-13791.
12. Hayes F., C. Daly and G.F. Fitzgerald 1990: Identification of the minimal replicon of *Lactococcus lactis* subsp. *lactis* UC317 plasmid pCI305. Appl. Environ. Microbiol. **56**,
10 202-209.
13. Hill, C., G. Venema, C. Daly and G.F. Fitzgerald 1988: Cloning and characterization of the tetracycline resistance determinant of and several promoters from within the conjugative transposon Tn919. Appl. Environ. Microbiol. **54**, 1230-
15 1236.
14. Hiratsuka, J., H. Shimada, R. Whittier, T. Ishibashi, M. Sakamoto, M. Mori, C. Kondo, Y. Honji, C.R. Sun, B.Y. Meng, Y.Q. Li, A. Kanno, Y. Nishizawa, A. Hirai, K. Shinozaki and M. Sugiura 1989: The complete sequence of the rice (*Oryza sativa*) chloroplast genome: intermolecular recombination
20 between distinct tRNA genes accounts for a major plastid DNA inversion during the evolution of cereals. Mol. Gen. Genet. **217**, 185-194.
15. Holo, H. and I.F. Nes 1989: High-frequency transformation, by electroporation, of *Lactococcus lactis* subsp. *cremoris* grown with glycine in osmotically stabilized media. Appl. Environ. Microbiol. **55**, 3119-3123.
25
16. Israelsen, H. and E.B. Hansen 1993: Insertion of Transposon Tn917 Derivatives into the *Lactococcus lactis* subsp
30 *lactis* Chromosome. Appl. Environ. Microbiol. **59**, 21-26.

17. Jahns, A., A. Schafer, A. Geiss and M. Teuber 1991:
Identification, cloning and sequencing of the replication
region of *Lactococcus lactis* subsp. *lactis* biovar *diacetylac-*
tis Bu2 citrate plasmid pSL2. FEMS Microbiol. Lett. 80, 253-
5 258.
18. Johansen, E. and A. Kibenich 1992: Characterization of
Leuconostoc isolates from commercial mixed-strain mesophilic
starter cultures. J Dairy Sci. 75, 1186-1191
19. Johansen, E. and A. Kibenich 1992a: Isolation and charac-
10 terization of IS1165, an insertion sequence of *Leuconostoc*
mesenteroides subsp. *cremoris* and other lactic acid bac-
teria,. Plasmid 27, 200-206.
20. Karabin, G.D. and R.B Hallick 1983: *Euglena gracilis*
chloroplast transfer RNA transcription units. Nucleotide
15 sequence analysis of a tRNAThr-tRNAGly-tRNAMet-tRNASer-
tRNAGln gene cluster. J. Biol. Chem. 258, 5512-5518.
21. Ma, D.P., Y.W. Yang and S. Hasnain 1989: Nucleotide se-
quence of *Chlamydomonas reinhardtii* mitochondrial genes
coding for tRNA gln (UUG) and tRNA met (CAU). Nucleic Acids
20 Res. 17, 1256-1256.
22. Macrina, F.L., R.P. Evans, J.A. Tobian and D.L. Hartley
1983: Novel shuttle plasmid vehicles for *Escherichia* - *Strep-*
tococcus transgenic cloning. Gene 25, 145-150.
23. Maid, U., R. Steinmueller and K. Zetsche 1992: Structure
25 and expression of a plasmid-encoded groEl homologous heat-
shock gene in athermophilic unicellular red alga. Curr.
Genet. 21, 521-525.
24. Marsh, J.L., M. Erfle and E.J. Wykes. 1984: The pIC
plasmid and phage vectors with versatile cloning sites for

- recombinant selection by insertional inactivation. *Gene* **32**, 481-485.
25. Nagano, Y., R. Matsuno and Y. Sasaki 1991: Sequence and transcriptional analysis of the gene cluster *trnQ-zfpA-psaI-ORF231-petA* in pea chloroplasts. *Curr. Genet.* **20**, 431-436.
26. Nakajima, N., H. Ozeki and Y. Shimura 1981: Organisation and structure of an *E. coli* tRNA operon containing seven tRNA genes. *Cell* **23**, 239-249.
27. Neuhard, J. and P. Nygaard 1987: Purines and Pyrimidines. In Neidhardt FC (ed), *Escherichia coli* and *Salmonella typhimurium*. American Society for Microbiology, Washington, DC, pp 445-473
28. Neuhaus, H. 1989: Nucleotide sequence of the chloroplast genes *fro* tRNA Gln and the 4 kD K polypeptide of photosystem II from mustard (S.a.). *Nucleic Acids Res.* **17**, 444-444.
29. Nilsson, D. and B. Hove-Jensen 1987: Phosphoribosylpyrophosphate synthetase of *Bacillus subtilis*. Cloning, characterization and chromosomal mapping of the *prs* gene. *Gene* **53**, 247-255
30. Nilsson, D. and E. Johansen 1994: A conserved sequence in tRNA and rRNA promoters of *Lactococcus lactis*. *Biochim. Biophys. Acta*. Submitted for publication.
31. Nilsson, D., Lauridsen, A.A., Tomoyasu, T. & Ogura, T. 1994. A *Lactococcus lactis* gene encodes a membrane protein with putative ATPase activity that is homologous to the essential *Escherichia coli* gene product. *Microbiology*, in press.

32. Nygaard, P. 1983: Utilization of preformed purine bases and nucleosides. In Munch-Petersen A (ed), Metabolism of nucleotides, nucleosides and nucleobases in microorganisms. Academic Press, Inc., New York, pp 27-93
- 5 33. Oda, K., K. Yamato, E. Ohta, Y. Nakamura, N. Nozato, T. Kohchi T., Y. Ogura, T. Kanegae, K. Akashi and K. Ohyama 1992: Gene organization deduced from the complete sequence of liverwort *Marchantia polymorpha* mitochondrial DNA. *J. Mol. Biol.* **223**, 1-7.
- 10 34. Oda, K., K. Yamato, E. Ohta, Y. Nakamura, M. Takemura, N. Nozato, K. Akashi and K. Ohyama 1992: Transfer RNA genes in the mitochondrial genome from a liverwort, *Marchantia polymorpha*: the absence of chloroplast-like tRNAs. *Nucleic Acids Res.* **20**, 3773-3777.
- 15 35. Ohyama, K., H. Fukuzama, T. Kohchi, T. Sano, H. Shirai, K. Umesono, Y. Shiki, M. Takeuchi, Z. Chang, S.I. Aota, H. Inokuchi and H. Ozeki 1988: Structure and organization of *Marchantia polymorpha* Chloroplast genome. I. cloning and gene identification. *J. Mol. Biol.* **203**, 281-298.
- 20 36. Ogasawara, N., S. Moriya and H. Yoshikawa 1983: Structure and organization of rRNA operons in the region of the replication region of the *Bacillus subtilis* chromosome. *Nucleic Acids Res.* **11**, 6301-6316.
- 25 37. Pedersen, M.L., K.R. Arnved and E. Johansen 1994: Genetic analysis of the minimal replicon of the *Lactococcus lactis* subsp. *lactis* biovar *diacetylactis* citrate plasmid. Submitted for publication.
- 30 38. Pittet, A.C. and H. Hottinger 1989: Sequence of an hexameric tRNA gene cluster associated with rRNA genes in *Lactobacillus bulgaricus*. *Nucl. Acid. Res.* **17**, 4873.
39. Ryan, M.J., E.L. Brown, R. Belangaje, H.G. Khorana and

- H.J. Fritz 1980: Cloning of two chemically synthesised genes for a precursor to the su⁺3 suppressor tRNA^{Tyr} in D. Söll, J.N. Abelson and P.R. Schimmel (eds.) Transfer RNA: Biological Aspects. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 245-258.
40. Sambrook, J., E.F. Fritsch and T. Maniatis 1989: Molecular cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
41. Siemeister, G., C. Buchholz and W. Hachtel 1990: Genes for the plastid elongation factor Tu and ribosomal protein s7 and six tRNA genes on the 73 kb DNA from *Astasia longa* that resembles the chloroplast DNA of *Euglena*. Mol. Gen. Genet. 220, 425-432.
42. Silhavy, T.J., M.L. Berman and L.W. Enquist 1984: Experiments with gene fusions. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
43. Simeneau, P., R. Wenzel, R. Herrmann and P.C. Hu 1990: Nucleotide sequence of a tRNA cluster from *Mycoplasma pneumoniae*. Nucleic Acids Res. 18, 2814-2814.
44. Strøman, P. 1992: Sequence of a gene (*lap*) encoding a 95.3-kDa aminopeptidase from *Lactococcus lactis* ssp. *cremoris* Wg2. Gene 113, 107-112.
45. Thorbjarnadóttir, S., H. Uemura, T. Dingermann, T. Rafnar, S. Thorsteindóttir, D. Söll and G. Eggertson 1985: *Escherichia coli* *supH* suppressor: Temperature-sensitive missense suppression caused by anticodon change in tRNA^{Ser}₂. J. Bacteriol. 161, 207-211.
46. Tsudzuki, J., K. Nakashima, T. Tsudzuki, J. Hiratsuka, M. Shibata, T. Wakasugi and M. Sugiura 1992: Chloroplast DNA of black pine retains a residual inverted repeat lacking rRNA

genes: nucleotide sequences of *trnQ*, *trnK*, *psbA*, *trnI* and *trnH* and the absence of *rps16*. *Mol. Gen. Genet.* 232, 206-214.

47. Wawrousek, E.F., N. Narasimhan and J.N. Hansen 1984: Two large clusters with thirty-seven transfer RNA genes adjacent to ribosomal RNA gene sets in *Bacillus subtilis*. *J. Biol. Chem.* 259, 3694-3702.

48. Wolfe, K.H., C.W. Morden, S.C. Ems and J.D. Palmer 1992: Rapid revolution of the plastid translational apparatus in a nonphotosynthetic plant: loss or accelerated sequence evolution of tRNA and ribosomal protein genes. *J. Mol. Evol.* 35, 304-317.

49. Yanase, H., H. Fukushi, N. Ueda, Y. Maeda, A. Toyoda and K. Tonomura 1991: Cloning, sequencing and characterization of the intracellular invertase gene from *Zymomonas mobilis*. *Agric. Biol. Chem.* 55, 1383-1390.

50. Yaniv M. and W.R. Folk 1975: The nucleotide sequences of the two glutamine transfer ribonucleic acids from *Escherichia coli*. *J. Biol. Chem.* 250, 3243-3253.

Applicant's or agent's file reference number	331469	International application No.	PCT/DK 94/00376
--	--------	-------------------------------	-----------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>31</u> , line <u>27</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution DSM-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1B D-38124 Braunschweig Germany	
Date of deposit 20 September 1993	Accession Number DSM 8557
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
As regards the respective Patent Offices of the respective designated states, the applicants request that a sample of the deposited microorganisms only be made available to an expert nominated by the requester until the date on which the patent is granted or the date on which the application has been refused or withdrawn or is deemed to be withdrawn.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <i>Anne Ryding</i>	Authorized officer

INDICATIONS RELATING TO DEPOSITED MICROORGANISMS
(PCT Rule 12bis)

Additional sheet

- 5 In addition to the microorganism indicated on page 80 of the description, the following microorganisms have been deposited with

DSM-Deutsche Sammlung von Mikroorganismen und
Cellkulturen GmbH
Mascheroder Weg 1b, D-38124 Braunschweig, Germany

- 10 on the dates and under the accession numbers as stated below:

	Accession number	Date of deposit	Description Page No.	Description Line No.
	DSM 8561	20 September 1993	34	30
15	DSM 8559	20 September 1993	39	15
	DSM 8558	20 September 1993	40	31
	DSM 8562	20 September 1993	42	12
	DSM 8560	20 September 1993	50	6
	DSM 9190	6 May 1994	57	20
20	DSM 9191	6 May 1994	57	33
	DSM 9192	6 May 1994	63	16
	DSM 9193	6 May 1994	64	33
	DSM 9194	6 May 1994	64	33

- 25 For all of the above-identified deposited microorganisms, the following additional indications apply:

- 30 As regards the respective Patent Offices of the respective designated states, the applicants request that a sample of the deposited microorganisms stated above only be made available to an expert nominated by the requester until the date on which the patent is granted or the date on which the application has been refused or withdrawn or is deemed to be withdrawn.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: Chr. Hansen's Laboratorium A/S
- (B) STREET: Bøge Allé 10-12
- (C) CITY: Horsholm
- (D) COUNTRY: Denmark
- (E) POSTAL CODE (ZIP): 2970

(ii) TITLE OF INVENTION: Lactic Acid Bacterial Suppressor Mutants
and Their Use as Selective Markers and as Means of
Containment in Lactic Acid Bacteria

(iii) NUMBER OF SEQUENCES: 39

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 89 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
GGAGCCATGG CAGAGTGGTA ATGCAACGGA CTCTAAATCC GTCGAACCGT GTAAAGCGGC      60
GCAGGGGTTC AAATCCCCTT GACTCCTTA                                         89
```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
TGAATTCAGA GGTTCGATGA CTTTGACC                                         28
```

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 28 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GGAATTCCTA ACAAAGACT ATTAACGC

28

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AAACTCTAGA GCAAGTATTC G

21

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CTTGCTCTAG AGTTTTTGTA G

21

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 33 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..33

(x) PUBLICATION INFORMATION:

- (A) AUTHORS: Macrina, F.L.
Evans, R.P.
Tobian, J.A.
Hartley, D.L.
- (B) TITLE: Novel shuttle plasmid vehicles for
Escherichia - Streptococcus transgenic cloning
- (C) JOURNAL: Gene
- (D) VOLUME: 25
- (F) PAGES: 145-150
- (G) DATE: 1983

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GAA CTA CAA AAA CTC AAT AGC AAG TAT TCG ATT
Glu Leu Gln Lys Leu Asn Ser Lys Tyr Ser Ile
1 5 10

33

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Glu Leu Gln Lys Leu Asn Ser Lys Tyr Ser Ile
1 5 10

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GCTAGAGTAA GTAGTT

16

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CCTTTACCTT GTCTACAAAC C

21

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 300 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

AATTGCGACA GTGTCTTCAT TTGAGGCTGC TTTAGAAGAA GCAATCAAGG AATATAATCT	60
ATCTATTTAA AGAGATTATA AAAAATTATT GATATTTCTT TGAAATAAAT AAGTTAAAAC	120
TTGAAATTTA TGAGGGTTTT TGGTAAAATA TTTCTTGTCG TCATCAAGCG ATCTGGGGT	180
ATAGCCAAGC GGTAAGGCAA GGGACTTTAA CTCCTCATG CGTTGGTTCG AATCCAGCTA	240
CCCCAGTAAA AAAACTTTAA AGGAAACGTT GTTCCTTTT TTCTTTTAC TAAAATATGA	300

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 300 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

TTTGTATAAA TATGCGTTTT TTGTTTTAGT TATTCTTATT TCATATTATT TCAGGAAGGT	60
AATTAAGTAT GGTATAATGA AATTAGATAA GGGAGCGGAG CCATGGCAGA GTGGTAATGC	120
AACGGACTCT AAATCCGTCG AACCGTGTA AGCGGCGCAG GGGTTCAAAT CCCCTTGACT	180
CCTTATAAGT AGAGTTCTTT ATTCTCAACT CTATTATATA AGAAAAATGA TAGTATTGAA	240
TACGCTTACT CCTTTTCCTC CTGTATGTAT AAGATTACAT CAGGAGGTTT TTTTATTCAA	300

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

TGGAGTATAG CCAAGTGGTA AGGCATCGGC CTTTGATGCC GAGAAACAAA GGTTCGAATC	60
CTTTTACTCC AG	72

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

TGGAGTATAG CCAAGTGGTA AGGCATCGGC CTTTGATGCC GAGAAACAAA GGTTCGAATC	60
CTTTTACTCC AG	72

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

TGGGGCATAG CCAAGTGGTA AGGCATTGGA CTTTGACTCC AAGATGCATG GGTTTGAATC 60
CTATTGCCCC AG 72

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 75 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TGGGGCGTGG CCAAGTGGTA AGGCAGCGGG TTTTGATCCC GTTATTCGGA GGTTTGAATC 60
CTTCCGTCCC AGCCA 75

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

TGGGGCGTGG CCAAGTGGTA AGGCAGCGGG TTTTGGTCCC GTTACTCGGA GGTTTGAATC 60
CTTCCGTCCC AG 72

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TGGGGCGTGG CCAAGTGGTA AGGCAACGGG TTTTGGTCCC GCTATTCGGA GGTTCGAATC 60
CTTCCGTCCC AG 72

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

TGGGGCGTAG CCAAGCGGTA AGGCAACGGG TTTTGGTCCC GCTATTCGGA GGTTCGAATC 60
CTTCCGTCCC AG 72

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TGGGGCGTGG CTAAGTGGTA AGGCAACGGG CTTTGGTCCC GCTATTCGTA GGTTCGAATC 60
CTTCCGTCCC AG 72

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

TGGGGCGTGG CCAAGCGGTA AGGCGGCGGG TTTTGGTCCC GTGATTCGGA GGTTCGAATC 60
CTTCCGTCCC AG 72

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

TGGGGCGTGG CCAAGCGGTA AGGCAGCAGG TTTTGATCCT GTTATTCGGA GGTTCGAATC 60
CTTCCGTCCC AG 72

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

TGGGGCGTCG CCAAGTGGTA AGGCTGCAGG TTTTGGTCCT GTTATTCGGA GGTTCGAATC 60
CTTCCGTCCC AG 72

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

TGAGGCGTAG CCAAGTGGTA AGGCAACGGG TTTTGGCCCT GTCATTCGGA GGTTCGAATC 60
CTCCCGCCTC AG 72

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

TGGGGCGTAG CCAAGCGGTA AGGCAACGGG TTTTGATCCC GTCATGCGCA GGTTCGAATC 60
CTGCCGCCCC AA 72

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TGAGGTGTAG CCAAGCGGTA AGGCAGCGGA CTTTGACTCC GCGATTCGTA GGTTCGAATC 60
CTACCACCTC AG 72

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

TGGGGTGTAG CCAAGTGGTA AGGTAACAGG TTTTGACCCT GTAATGCGAG GGTTCAAATC 60
CTTCCACCTC AG 72

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 75 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

TGGGGTATCG CCAAGCGGTA AGGCACCGGT TTTTGATAACC GGCATTCCCT GGTTCGAATC 60
CAGGTACCCC AGCCA 75

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 75 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

TGGGGTATCG CCAAGCGGTA AGGCACCGGA TTCTGATTCC GGCATTCCGA GGTTCGAATC 60
CTCGTACCCC AGCCA 75

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 75 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

TGGGCTATAG CCAAGCGGTA AGGCAAGGGA CTTTGACTCC CTCATGCGCC GGTTCGAATC 60
CTGCTAGCCC AACCA 75

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 75 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

TGGGATGTAG CCAAGCGGTA AGGCAATAGA CTTTGACTCT ATCATGCGAT GGTTCGATCC 60
CATCCATCCC AGCCA 75

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

TGGGCTATAG CCAAGCGGTA AGGCAACGGA CTTTGACTCC GTCATGCGTT GGTTCGAATC 60
CAGCTAGCCC AG 72

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

TGGGGTATAG CCAAGCGGTA AGGCAAGGGA CTTTAACTCC CTCATGCGTT GGTTCGAATC 60
CAGCTACCCC AG 72

(2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

CGAATTCATA AATGCTTTCC CCTATTC

27

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

CGAATTCCTG AAATTTATGA GGGTTTTTGG

30

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 69 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

GAATTCCTCGG GGATCCGTCG ACCTGCAGCC AAGCTTTCGC GAGCTCGAGA TCTAGATATC

60

GATGAATTC

69

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2006 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

GAATTCCCGG GGATCCGTCG ACCTGCAGCC AAGCTTTCGC GAGCTCGAGA TCTAGATATC	60
GATGAATTCC TAACAAAAGA CTATTAACGC TTAATTCCTC ATTTTTCTT GTCGATTTTC	120
GGTCGGTTGA ACTTTTTTA TTTTGTAG TCTTTTTTG ATAACTTTT GTTCTCAAG	180
GTTTAGGACG ATCGAACCAC TATTGTTTT TTGTCGATT TCGGTCGGCA AAACTTTAA	240
ATGGTATTGA ACGGTCTGTT TAGCTAGTCC TAGCTCGTCC GCCAACTCTT TTATCGTTTT	300
TAAGTCTTCA CTCATGGTTT AAGTCCTGCC TTTTAACCGT TGGCAGATAT TGTTCATGG	360
CTTTTTTAAG ATATTCGCT ACATTACGTT TAGAATAGGC TTCTTTTTG CTGGCAACAT	420
AAGACAAGTG GTCTTTGACA CCATTAGCC CTCCTAATTC TTTCAGTTCG TCATAAGCG	480
GATAACATT CTCTGTAAG CCTACCATTG TGGCTGTATC CATAATATCA TTCATGCCAA	540
TTAAGAAATT TTCAGATAAA AGTCTGTAT ATTTACTTC CATTGCCTGT TTTAGTAAGT	600
CAGCTTCATT TCTTGATTT TGCTTTTAT CGTCTTGATA GTCTTTATCT CCCAACTGT	660
AACTGTTATC GTCTGCCATG CGTTTCTCT CAATATGAAA GACAATAGAG TCAATGCTCC	720
GCCCTGCTTT CTTTTCTCA TAGGTTACAT TAAAAGAGGT GTGAGCGTTG ATTTCTTCAA	780
TTGCTTTTTT TAATACTCTA GTTTCAAAAT GGGGAAAATG TTGATGTTCA TTTATTGTAT	840
CAGTTATTC TCGCAATTCT TTCACTTTA TTGAGGGGT GCGGTAGGAT TCCACTTGT	900
CAACTCTCCG TCCCCCTTC ACGCTGTAAT GTTCGTATTG GTTATAATTC ATGGATAACC	960
AACGATACAA AATAATCGAA TACTTGCTAT TGAGTTTTG TAGTTCGGAA ATTTTATATT	1020
GAGTAAATTC TGCTTTTAAA TCAATCAGAT AGGGCATAAT GGCTTGGTCA AAACGTATTG	1080
TTACTTCATC GTTATAATCG TTCCATTTA CATAAGGAAT AGGCACAATG CTTTCATACT	1140
CAATACCTAG TTTCTTATCA GCTTTAATAT TGAAAAAGGC TTGCTTTTGC ATATAATTAA	1200
CTGCTTCTTT GAATTGACTA TGCTTACTGC TAGACGATAC TTCAAAAAAT TAAAAAGTT	1260
CAGATTTTAA AAGATAAACA GTATTATTT TTGGGGGTTT TTCGGTATCA ATACAAGACA	1320
CGGCTAACTC AAACATTTTT AAAGCTGTTT TTTGCATTTT AGCCACACTT TGAATTAAAG	1380
CGTTATGCTC CACTACTTG CGTTTTCTA ATTCAATCAA GGTCAGCACC TGCTTTTGT	1440
TGTTTTGTTT TTCTGGTATA ATCATAGTAT AAATACGCTC CTTTGCGTGT TTTAGTAGTA	1500
GCATAGAGAA AGTCATTTCA TAGTGAGTTT TCTCTATGCT TTTATTATAC TATATACAGT	1560
ACACAAATAC AAAAGTCGTG CTGTGTACAT CGATTTTGT GACTCTATAC ATCGATTTTT	1620
GTGACTCTAT ACATCGATTT TTGTGACTGT TTAATTTCTA TAACTAGCGA AAACACTGCC	1680

TTTTTTTTCA CGCAAAGAA CAAAAGATTA AAATATATAT GATAAATATA TAGTAGGCTT	1740
CGCCTTTTTT TATTTTTTTC AAAAATTTAA AACCAAAGGT CAAAGTCATC AAACCTCTGA	1800
ATTCTTGAAA TTTATGAGGG TTTTGGTAA AATATTTCTT GTCGTCATCA AGCGATCTTG	1860
GGGTATAGCC AAGCGGTAAG GCAAGGGACT TTAACCTCCCT CATGCGTTGG TTCGAATCCA	1920
GCTACCCAG TAAAAAACT TTAAAGGAAA CGTTGTTTCC TTTTTTCTTT TTAATAAAAT	1980
ATGATAGAAT AGGGGAAAGC ATTTAT	2006

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 46 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

CTTGAAATTT ATGAGGGTTT TTGTAAAATA TTTCTTGTCG TCATCA	46
--	----

(2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1311 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

ATGACAGTAA CATCAGATTT CACACAAAAA CTCTACGAAA ATTTTGCAGA AAATACAAAA	60
TTGCGTGCGG TGGAAAATGC CGTGACTAAA AATGGTTTGC TTTCATCACT CGAAGTCCGT	120
GGTTCACATG CAGCAAATTT GCCTGAGTTT TCAATTGACT TGACAAAAGA CCCTGTAACG	180
AATCAAAAAC AATCTGGTCG TTGCTGGATG TTTGCTGCTT TGAACACTTT CCGTCATAAA	240
TTTATCAATG AATTTAAAAC AGAGGATTTT GAGTTTTTAC AAGCTTACAC TTTCTTCTGG	300
GATAAATATG AAAAATCAAA CTGGTTCATG GAACAAATTA TTGGTGATAT TGAAATGGAC	360
GATCGTCGTT TGAAATTCCT TTTACAAACA CCACAACAAG ATGGCGGCCA ATGGGATATG	420
ATGGTTGCAA TTTTGGAAAA ATATGGAATT GTTCCCAAAG CTGTTTATCC TGAATCACAA	480
GCTTCAAGTA GCTCACGTGA ATTGAATCAA TACTTGAATA AACTACTCCG TCAAGATGCT	540
GAAATTTTGC GTTATACAAT TGAGCAAGGT GGAGATGTTT AAGCAGTTAA AGAAGAACTT	600

TTGCAAGAAG TCTTTAATTT CCTTGCGGTA ACTTTAGGTT TGCCACCACA AAATTTTGAA	660
TTTGCTTTCC GTAATAAAGA TAATGAATAC AAAAAATTTG TTGGTAGTCC AAAAGAATTT	720
TACAATGAAT ATGTTGGAAT TGATTTGAAT AATTATGTGT CAGTAATCAA TGCTCCAACT	780
GCTGACAAAC CTTATAATAA GAGCTACACA GTTGAGTTTC TTGGAAATGT TGTCGGTGGT	840
AAAGAAGTGA AACATTTGAA TGTTGAAATG GACCGCTTTA AAAAAATGGT CATTGCCCAA	900
ATGCAAGCTG GTGAAACAGT TTGGTTTGGT TGTGACGTGG GTCAAGAATC AAATCGTTCA	960
GCAGGACTTT TGACAATGGA TTCTTATGAT TTCAAATCTT CATTTGGATAT TGAATTTACT	1020
CAAAGCAAAG CAGGACGTCT TGACTATGGT GAGTCGTGA TGACGCATGC CATGGTTTTA	1080
GCGGGTGTG ATTTAGATGC TGACGGAAAT TCAACTAAAT GGAAAGTTGA AAATTCATGG	1140
GGTAAAGATG CGGGTCAAAA AGGATATTTT GTTGCTCTG ATGAATGGAT GGATGAATAT	1200
ACTTATCAAA TTGTTGTCCG TAAAGACCTT TTAAGTGAAG AAGAATTGGC TGCTTACGAA	1260
GAGAAACCTC AAGTACTTCT ACCATGGGAC CCAATGGGTG CTTTAGCTTA A	1311

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1419 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

ATGACAACTA TTGATTTTAA AGCTGAAGTT GAAAAGCGTA AGGACGCTTT GATGGAAGAT	60
TTGTTTAGCC TTTTGCGCAT TGATTCTGCA ATGGATATGG AACATGCAGA TGCTGAAAAA	120
CCATTTGGCC CTGGTCCAAG AAAAGCTTTG GATGCATTCT TGAAAATTGC CGAACGTGAT	180
GGTTATACAA CTAAAAATTA TGATAACTAT GTTGACATT TTGAATATGA AAACGGAGCA	240
AATGCTGATG CCGAAGTTCT CGGAATTATT GGTCACTTAG ATGTTGTTCC TGCTGGTTCC	300
GGTTGGGATT CAAATCCATT TGAGCCAGAA ATCCGTAATG GGAATCTCTA TGCTCGTGGT	360
GCTTCTGATG ATAAAGGACC AACAGTTGCA TGTTACTATG CACTCAAATT TTTGAAAGAA	420
CTTAATCTTC CATTTATCTAA AAAAAATCCGT TTCATCGTTG GTACAAACGA AGAAACAGGT	480
TGGGCAGATA TGGATTACTA CTTTGAGCAC TGTGAATTGC CGTTGCCTGA TTTTGGTTTC	540
TCACCTGATG CTGAGTTCCC AATTATCAAT GGTGAAAAAG GGAATATCAC AGAATATCTC	600
CATTTCTCAG GTAAAAATGC TGGTCAAGTT GTTCTTCACA GCTTTAAAGC AGGTCTTGCA	660

GAAATATGG TTCCAGAATC AGCAACTGCA GTGATTTTCAG GTGCTAAAGA TTTAGAAGCT	720
GCACTTGAAA AATTTGTAGC TGAACATGCA AGCAAAAATC TTCGTTTTGA CCTTGAAGAG	780
GCTGATGGAA AAGCAACAAT TACGCTTTAT GGTAAATCAG CGCATGGTGC GATGCCAGAA	840
AAAGGGATTA ATGGAGCAAC TTATCTTACT TTGTTCTTGA ATCAATTTGA CTTTGCTGAC	900
GGTGCTGCTG CCTTCATTAA AGTTGGGGCT GAAAACTTC TTGAAGATCA TGAAGGTGAA	960
AAATTAGGAA CAGCTTTTAT TGATGAATTG AAGGGAAATA CCTCAATGAA TGCTGGTGTT	1020
TGGTCATTTG ATGAAAATGG TGAAGGTAAA ATCGCCCTCA ATTTCCGTTT CCCACAAGGG	1080
AACAGCCCAG AGCGTATGCA AGAAATTCTT GCTAAACTTG ATGGGGTTGT TGAAGTTGAA	1140
CTTTCAAAAC ACCTCCACAC ACCTCACTAT GTTCCAATGT CAGACCCACT TGTATCAAGA	1200
TTGATTGATG TTTATGAAAA ACACACTGGT CTTAAAGGCT ATGAAACAAT CATTGGTGGT	1260
GGAACTTTCG GTCGTCTGTT GGAACGTGGT GTTGCTTATG GAGCAATGTT TGAAGGAGAA	1320
CCAGATTCAA TGCACCAAGC GAATGAAATG AAACCTGTTG AGAATATCTA CAAAGCGGCA	1380
GTGATTTATG CTGAAGCAAT TTATGAACTT GCAAAATAA	1419

CLAIMS

1. A method of isolating a nonsense suppressor-encoding lactic acid bacterium, comprising the steps of

5 (i) mutagenizing a replicon capable of replicating in a lactic acid bacterium, said replicon comprising a gene encoding a selectable marker which is expressible in the lactic acid bacterium,

10 (ii) selecting from the mutagenized replicon of (i) a replicon containing a nonsense mutation in the gene encoding the selectable marker,

(iii) mutagenizing a lactic acid bacterium which does not encode a nonsense suppressor,

15 (iv) introducing the replicon of step (ii) into said mutagenized lactic acid bacterium, and

(v) selecting from the mutagenized lactic acid bacterium of (iv) a nonsense suppressor-encoding transformed lactic acid bacterium in which the selectable marker is expressed.

20 2. A method according to claim 1 wherein the transformed lactic acid bacterium in a further step is cured of the replicon introduced in step (iv).

25 3. A method according to claim 1 wherein the nonsense suppressor is selected from a group consisting of an amber suppressor and an ochre suppressor.

4. A method according to claim 1 wherein the nonsense suppressor-encoding gene is a tRNA-encoding gene.

5. A method according to claim 1 wherein the nonsense-suppressor gene is located on the chromosome.

6. A method according to claim 1 wherein the replicon being mutagenized in step (i) is selected from a plasmid and a bacteriophage.

7. A method according to claim 1 wherein the selectable
5 marker of the replicon being mutagenized in step (i) is selected from antibiotic resistance and auxotrophy.

8. A method of isolating a nonsense suppressor-encoding lactic acid bacterium, comprising the steps of

10 (i) mutagenizing a replicon without nonsense mutations but containing a selectable marker, which plasmid is inherently capable of replicating in a lactic acid bacterium,

(ii) selecting from step (i) a replicon containing a
15 nonsense mutation rendering the replicon incapable of replicating,

(iii) mutagenizing a lactic acid bacterium which does not encode a nonsense suppressor,

(iv) introducing into said mutagenized lactic acid bacterium the replicon of step (ii), and

20 (v) selecting a transformed lactic acid bacterium in which the introduced replicon is capable of replicating.

9. A method according to claim 8 wherein the transformed lactic acid bacterium in a further step is cured of the replicon introduced in step (iv).

25 10. A method according to claim 8 wherein the replicon is selected from a plasmid and a bacteriophage.

11. A method according to claim 10 wherein the replicon being mutagenized in step (i) is a wildtype plasmid isolated from a lactic acid bacterium.
12. A method according to claim 10 wherein the replicon is a
5 citrate plasmid.
13. An isolated pure culture of a lactic acid bacterium comprising a gene coding for a nonsense suppressor.
14. A culture according to claim 13 wherein the gene coding
10 for a nonsense suppressor is a gene coding for tRNA.
15. A culture according to claim 13 wherein the gene coding for the nonsense suppressor is located on the chromosome.
16. A culture according to claim 13 wherein the gene coding for a nonsense suppressor is located on a non-chromosomal
15 replicon.
17. A culture according to claim 16 wherein the gene is isolated from a lactic acid bacterium.
18. A culture according to claim 13 wherein the nonsense suppressor is selected from the group consisting of an amber
20 suppressor and an ochre suppressor.
19. A culture according to claim 13 which further comprises a nonsense mutation being suppressible by the nonsense suppressor.
20. A culture according to claim 19 wherein the nonsense
25 mutation is located on a replicon different from the one containing the gene coding for a nonsense suppressor.
21. A culture according to claim 13 wherein the lactic acid bacterium is selected from *Lactococcus* spp., *Streptococcus*

spp., *Lactobacillus* spp., *Leuconostoc* spp., *Pediococcus* spp. and *Bifidobacterium* spp.

22. A culture according to claim 21 wherein the lactic acid bacterium is *Lactococcus lactis*.

5 23. A culture according to claim 13 wherein the suppressor is one suppressing a nonsense mutation which in the absence of a nonsense suppressor capable of suppressing the mutation, confers auxotrophy.

10 24. A culture according to claim 23 wherein the nonsense mutation is in a gene involved in the synthesis of purine nucleotides from their precursors.

25. A culture according to claim 24 wherein the lactic acid bacterium is a *pur* mutant.

15 26. A culture according to claim 13 containing at least 10^9 colony forming units of the lactic acid bacterium per g.

27. A culture according to claim 26 which is selected from a frozen culture and a freeze-dried culture.

20 28. A culture according to claim 13 wherein the gene coding for a nonsense suppressor is under the control of a regulatable promoter.

29. A culture according to claim 28 wherein the regulatable promoter is a promoter not naturally related to the gene.

30. A composition comprising an isolated pure culture of a lactic acid bacterium as defined in claim 20, and a carrier.

25 31. A composition according to claim 30 containing at least 10^9 colony forming units of the lactic acid bacterium per g.

32. Use of a composition as defined in claim 30 as a starter culture in the preparation of a food product selected from a dairy product, a vegetable product, a meat product and a bakery product.

5 33. A plasmid comprising lactobacterial DNA and capable of replicating in a lactic acid bacterium, the plasmid comprising a gene coding for a nonsense suppressor.

34. A plasmid according to claim 33 wherein the gene coding for a nonsense suppressor is derived from the chromosome of a
10 lactic acid bacterium.

35. A plasmid according to claim 33 wherein the gene coding for a nonsense suppressor is a gene coding for tRNA.

36. A plasmid according to claim 35 wherein the nonsense mutation suppressor is selected from the group consisting of
15 an amber suppressor and an ochre suppressor.

37. A method of confining an extrachromosomal replicon capable of replicating in lactic acid bacteria to a first kind of lactic acid bacterial cells, where said replicon could be naturally transferred to a second kind of lactic acid bacterial cells, which method comprises providing the first kind
20 of lactic acid bacterial cells as cells containing a nonsense suppressor-encoding gene, the cells being transformed with the replicon in the form of a nonsense mutant having lost its capability of replicating in lactic acid bacterial cells, the
25 gene product of the nonsense suppressor-encoding gene being capable of restoring the capability of the replicon to replicate in lactic acid bacterial cells whereby, if a cell of the second kind which does not contain a nonsense suppressor gene encoding a gene product capable of restoring the capability
30 of the nonsense mutant of the replicon to replicate in lactic acid bacteria, receives said extrachromosomal replicon, the replicon will not replicate in the second kind of lactic acid bacterial cell.

52. A method according to claim 48 wherein the nonsense suppressor-encoding gene is regulated so that the expression of the gene is decreased or stopped.

53. A method according to claim 52 wherein the lactic acid bacteria contain a prophage and the nonsense mutation is located in a gene coding for a gene product inhibiting the entering of the prophage into its lytic cycle whereby, when the expression of the gene coding for the nonsense suppressor is decreased or stopped, the phage enters the lytic cycle, causing the lactic acid bacteria to die.

54. A method according to claim 52 wherein the nonsense mutation is located in a gene coding for a gene product, the expression of which is required for growth of the bacteria, whereby, when the expression of the gene coding for the nonsense suppressor, is decreased or stopped, the gene product which is required for growth of the bacteria is no longer expressed, causing growth of the lactic acid bacterial cells to cease.

55. A culture according to claim 20 wherein the lactic acid bacterium comprises a vector consisting of DNA from a lactic acid bacterium or a plasmid naturally occurring in a lactic acid bacterium, comprising a selectable marker, a replication region and at least one restriction site.

56. A culture according to claim 55 wherein the selectable marker is the suppressor gene.

57. A culture according to claim 56 wherein the vector is pFG1.

58. A culture according to claim 56 wherein the promoter for the suppressor gene is mutated whereby the expression of the gene is altered to an extent where the growth of the lactic acid bacterium is not decreased relative to that of a bacte-

rium hosting a vector in which the promoter for the suppressor gene is not mutated.

59. A culture according to claim 55 wherein the vector further comprises an inserted gene coding for a desired gene
5 product.

60. A culture according to claim 59 wherein the gene product is a peptidase

61. A culture according to claim 55 wherein the vector is selected from pFG2, pFG3, pFG4, pFG5 and pFG6.

52. A method according to claim 48 wherein the nonsense suppressor-encoding gene is regulated so that the expression of the gene is decreased or stopped.

53. A method according to claim 52 wherein the lactic acid bacteria contain a prophage and the nonsense mutation is located in a gene coding for a gene product inhibiting the entering of the prophage into its lytic cycle whereby, when the expression of the gene coding for the nonsense suppressor is decreased or stopped, the phage enters the lytic cycle, causing the lactic acid bacteria to die.

54. A method according to claim 52 wherein the nonsense mutation is located in a gene coding for a gene product, the expression of which is required for growth of the bacteria, whereby, when the expression of the gene coding for the nonsense suppressor, is decreased or stopped, the gene product which is required for growth of the bacteria is no longer expressed, causing growth of the lactic acid bacterial cells to cease.

55. A culture according to claim 20 wherein the lactic acid bacterium comprises a vector consisting of DNA from a lactic acid bacterium or a plasmid naturally occurring in a lactic acid bacterium, comprising a selectable marker, a replication region and at least one restriction site.

56. A culture according to claim 55 wherein the selectable marker is the suppressor gene.

57. A culture according to claim 56 wherein the vector is pFG1.

58. A culture according to claim 56 wherein the promoter for the suppressor gene is mutated whereby the expression of the gene is altered to an extent where the growth of the lactic acid bacterium is not decreased relative to that of a bacte-

rium hosting a vector in which the promoter for the suppressor gene is not mutated.

59. A culture according to claim 55 wherein the vector further comprises an inserted gene coding for a desired gene
5 product.

60. A culture according to claim 59 wherein the gene product is a peptidase

61. A culture according to claim 55 wherein the vector is selected from pFG2, pFG3, pFG4, pFG5 and pFG6.





Fig. 1

**Fig. 2**

3/8

```

10      30      50
AATGCGACAGTGTCTTCATTGAGGCTGCTTTAGAGAAGCAATCAAGGAATATAATCT
          ***** #####
70      90      110
ATCTATTAAAGAGATTATAAAAAATTATTGATATTCTTTGAAATAAATAAGTTAAAC
          ***** #####
pFDi17&18 pFDi19      150      170
TTGAAAATTATGAGGGTTTTTGGTAAAAATAATTTCTTGTGTCATCAAGCGATCTTGGGGT
          #####
190      210      230
ATAGCCCAAGCGGTAAGGCAAGGGACTTTAACTCCCTCATGCCGTTGGTTCGAATCCAGCTA
          <----->
250      270      290
CCCCAGTAAAAAACTTAAAGGAACGTTGTTTCCTTTTCTTTTACTAAAAATATGA
          <----->

```

Fig. 3

4/8

10 30 50
TTTGTATAAATATGCGTTT TTTTGGTTT TAGTTATTCTTATTT CATATATTTCAGGAAGGT

70 90 110

AATTAACTATGGGTATAATGAAATTAGATAAAGGAGCGGAGCCCATGGCAGAGTGGTAATGC

130 150 170
AACGGACTCTAAATCCGTCGAACCGTGTAAGCGGCGCAGGGGTTCAAATCCCCTTGACT
190 210 230
CCTTATAAGTAGAGTCTTTATTTCTCAACTCTATTTATATATAAGAAAAATGATAGATTGAA
250 270 290
TACGCTTACTCCTTTTCCCTCGTATGTATAAGATTACATCAGGAGGTTTTTTTATTTCAA
-----> <-----

Fig. 4




Fig. 5A





Fig. 5B



8/8




Fig. 7

INTERNATIONAL SEARCH REPORT

 Intern. Application No
 PCT/DK 94/00376

 A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C12N15/74 C12N15/68 C12N1/21 A23C3/08 //(C12N1/21,
 C12R1:225)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 C12N A23C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 309 961 (HOECHST JAPAN LIMITED) 5 April 1989 see page 3, line 6 - line 19 see page 3, line 45 - page 4, line 34 ---	1,3,4, 6-8,10
A	US,A,4 687 737 (PHILIP A. SHARP ET AL.) 18 August 1987 see column 2, line 15 - line 24 see column 2, line 58 - column 3, line 7 see column 9, line 56 - column 10, line 2 ---	1,3,4,8, 48
A	EP,A,0 355 036 (NEDERLANDS INSTITUUT VOOR ZUIVELONDERZOEK) 21 February 1990 see page 3, line 48 - page 4, line 54 -----	

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

2 January 1995

Date of mailing of the international search report

25.01.95

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Montero Lopez, B

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK 94/00376

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0309961	05-04-89	JP-A- 1086875	31-03-89
US-A-4687737	18-08-87	NONE	
EP-A-0355036	21-02-90	NL-A- 8801529	02-01-90